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ABSTRACT 
 
Correlation of In-Vitro Drug Dissolution and In-Vivo Drug Absorption of Various 
Therapeutically Equivalent Pharmaceutical Solid Dosage Forms of Simvastatin 
 
 Simvastatin is a well known anti-cholesterol drug that is commercially available 
in the United States in various strengths including Simvastatin Tablets, USP 80 mg, that 
are under the brand name Zocor (manufactured by Merck Pharmaceutical Co.) and 
various generic equivalent products for example those manufactured by Teva 
Pharmaceuticals, Inc. and Dr. Reddy’s Laboratories, Ltd.  When generic products are 
tested in the United States, they must be found to be equivalent with their branded 
products by the FDA.  Therefore, generic Simvastatin Tablets, USP 80 mg, have been 
tested and approved by the FDA as equivalents to, and substitutable with, the branded 
Zocor tablets of the same strength.  The Teva and Reddy’s generic Simvastatin products 
have also been found to be bioequivalent to the branded Zocor product in FDA-approved 
in-vivo clinical studies involving healthy human subjects (dosed under fasting and non-
fasting conditions).   
In this study, the drug dissolution profiles of the brand Zocor and the generic 
Teva and Reddy’s Simvastatin 80 mg tablets were assessed and compared using twelve 
different in-vitro dissolution tests consisting of three different dissolution media (i.e., 
three aqueous solutions of 0.5% w/v SLS in Phosphate Buffer pH 7.0, Purified Water, or 
Acetate Buffer pH 4.5, respectively), two different volumes of dissolution medium (i.e., 
500 or 900 mL per dissolution vessel), and two different agitation speeds (i.e., paddles 
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rotating at 35 or 50 rpm).  The 10-min, 20-min and 30-min drug dissolution rates of each 
of the two generic products were statistically compared to those of the reference Zocor 
product using a t-test to evaluate similarities or significant differences between the 
compared drug dissolution rates of the Teva vs. Zocor and Reddy’s vs. Zocor product 
pairs under evaluation.   
It was established in this study that two dissolution tests in particular possess 
promising in-vitro/in-vivo correlation characteristics, which should be further evaluated.  
Specifically, it was found that two dissolution tests consisting of 900 mL (per vessel) of 
an aqueous dissolution medium comprising of 0.5% w/v SLS in either Phosphate Buffer 
pH 7.0 or Acetate Buffer pH 4.5, maintained at 37oC and agitated via paddles rotating at 
a speed of 35 rpm, have produced statistically similar 10-min, 20-min and 30-min drug 
dissolution rates displayed by all three products.  These results show that the use of these 
two in-vitro dissolution tests may have reliable predictive in-vivo power, thereby possibly 
facilitating the timely and cost-efficient development of new generic immediate-release 
Simvastatin products that would be bioequivalent to their branded Zocor counterpart. 
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INTRODUCTION AND LITERATURE BACKGROUND 
 
Simvastatin 
Simvastatin is a lipid-lowering drug, which is used for treating patients with 
hypercholesterolemia, a form of hyperlipidemia, in order to prevent atherosclerosis, 
cardiovascular disease, and stroke (Schmitz and Langmann, 2006).  Cardiovascular 
disease is still the leading cause of death worldwide today (ibid.).  When diet and 
exercise are not enough to reduce cholesterol levels, statins are the most prominent 
medication prescribed.  Cholesterol is important for the body because it aids in the 
production of hormones, vitamin D and bile acids that facilitate digestion of fats in the 
intestines.  However, bad cholesterol, also known as low density lipoprotein (LDL), 
adheres to arteries and results in the blockage of proper oxygenated blood flow.  
Therefore, elevated levels of LDL increase the risk of heart disease, heart attack and 
stroke.  With the use of lipid-lowering therapy, however, statins have been able to 
decrease mortality caused by high levels of cholesterol by inhibiting the rate-limiting step 
of cholesterol biosynthesis.   Simvastatin is one of the most important and highly 
commercialized representatives of the statin family, which consists of potent 3-
hydroxymethyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.   
Simvastatin is administered as a lipophilic lactone pro-drug and converted in-vivo 
to its corresponding beta-hydroxyacid form (Figure 1).  Beta-hydroxyacid is its active 
metabolite, which is the inhibitor of HMG-CoA reductase.  A pro-drug is a 
pharmacological substance administered in an inactive form to later be metabolized to its 
active metabolite (Mitchel, 1992).  Administered as a lactone pro-drug increases its 
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selective uptake by the liver, which is the site of action of cholesterol biosynthesis and of 
course drug metabolism.    Simvastatin’s pro-drug status also allows for low system 
availability of the active drug, which also helps in lowering adverse effects (Mitchel, 
1992).  Another advantage is that it can be taken without regard to food (Davidson and 
Toth 2004).  
Simvastatin is structurally similar to and also, a semi-synthetic chemical 
modification of Lovastatin (see Figure 1), with the addition of a methyl group on the ester 
side chain (Boccuzzi, 2000).  Simvastatin is a fermentation product of Aspergillus terreus 
(Blum 1994, p. 3D).  The chemical name is butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-
hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-
naphthalenyl ester  (Merck, 2012).   Simvastatin’s empirical formula is C25H38O5, and its 
molecular weight is 418.57; it’s a white to off-white, non-hygroscopic, crystalline powder 
that is virtually insoluble in water, and freely soluble in methanol and ethanol (Merck, 
2012).   Zocor (Simvastatin Tablets, USP) is available for oral administration in 5 mg, 10 
mg, 20 mg, 40 mg and 80 mg strengths in the form of tablets with the following inactive 
ingredients: ascorbic acid, citric acid, hydroxypropyl cellulose, hypromellose, iron 
oxides, lactose, magnesium stearate, microcrystalline cellulose, starch, talc, and titanium 
dioxide (ibid.).  Other commonly available forms of statins and members of the statin 
family are: Atorvastatin, Cerivastatin, Fluvastatin, Lovastatin, Mevastatin, Pitavastatin, 
Pravastatin and Rosuvastatin. 
Statin therapy is the choice for individuals with high LDL cholesterol levels.  
They competitively inhibit the rate-limiting step of cholesterol synthesis in the liver (see 
Figure 2).  Acetyl-CoA initiates the reactions that comprise the mevalonate pathway that 
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leads to the production of farnesyl-PP, the precursor for cholesterol (Bentinger et al., 
2010).  Statins inhibit HMG-CoA reductase from converting HMG-CoA to Mevalonic 
acid. 
 
 
 
 
Figure 1:  Chemical structure of Simvastatin and Lovastatin (Shitara and Sugiyama, 
2006; with permission of publisher). 
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Figure 2:  Biosynthesis of cholesterol.  Cholesterol is synthesized from acetyl coenzyme 
A. These drugs act by competitively inhibiting this enzyme from converting HMG-CoA 
to mevalonate, which is the rate-limiting step in cholesterol biosynthesis (Shitara and 
Sugiyama, 2006; with permission of publisher). 
 
 
 
 
 
The inhibition of cholesterol synthesis by statins promotes the up-regulation of 
LDL receptor expression, leading to a decrease in LDL levels in plasma.  All statins 
lower triglyceride levels up to 30-50%, which renders them extremely useful agents for 
lipid lowering therapy (Schmitz and Langmann, 2006).  It is important to note that LDL 
functions to transport cholesterol away from the liver to other cells of the body, whereas 
High Density Lipoprotein (HDL), the “Good Cholesterol”, functions to transport 
cholesterol back to the liver.  Therefore, it is imperative to take quick action against 
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hyperlipidemia in order to keep LDL levels as low as possible to avoid cholesterol 
buildup in the heart and to hinder further complications.  
Initially, all drugs undergo biotransformation prior to entering systemic 
circulation.  There are two stages, the pre-hepatic where biotransformation takes place in 
the intestinal wall by the columnar epithelial cells and secondly by the liver. The liver is 
the epitome of drug metabolism in which all drugs are targeted to undergo first pass 
metabolism (Blum, 1994).   Oral bioavailability of Simvastatin is extremely low (<5%), 
due to its extensive CYP3A mediated first pass metabolism in the intestinal wall and liver 
(Neuvonen et al., 2006).  CYP3A4 is part of the CYP 450 system involved in drug 
metabolism (see Figure 3).  CYP3A4 oxidizes and hydrolyzes simvastatin’s lactone form 
to its inactive or moderately active metabolites (Neuvonen et al., 2006). To avoid toxic 
serum levels, it is important not to use other drugs that are CYP3A4 inhibitors with 
simvastatin because it will lead to strong increases in its concentrations and elicit 
unwanted drug interactions (Neuvonen et al., 2006). 
Adverse effects caused by statins correlate with their plasma levels.  Therefore, it 
is imperative to control statin plasma levels and to avoid concomitant use of statins with 
CYP3A4 inhibitors or inducers. CYP3A4 inhibitors include but are not limited to, 
Itraconazole, Ketoconazole, Posaconazole, HIV protease inhibitors, Boceprevir, 
Telaprevir, Eythromycin, Clarithromycin, Telithromycin, Nefazodone, Verapamil, 
Dilitazem, Amiodarone, Amlodipine, Ranolazine, Gemfibrozil, Cyclosporine Danazol 
and grapefruit juice (Merck, 2012).           
Statins are generally well-tolerated drugs with mild dyspepsia or gastrointestinal 
disturbances (Neuvonen et al., 2006).  There are more severe clinical conditions however, 
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that consist of myotoxic adverse reactions such as myopathy and infrequently, 
rhabdomyolysis (Neuvonen et al., 2006).  The probability of being diagnosed with 
myopathy including rhabdomyolysis, is dose related and is greater in patients on 
Simvastatin 80 mg than in lower doses (Merck, 2012).  Myopathy is a form of muscle 
weakness whereas rhabdomyolsis is the breakdown of muscle fibers releasing myoglobin 
into the bloodstream, which has hazardous affects on the kidney (Bellosta et al., 2004).  
In contrast, Rifampin, a drug used to treat tuberculosis, is a CYP3A4 inducer, which 
decreases the levels of statins in plasma and prevents the patient from having a 
therapeutic effect after Simvastatin administration (Neuvonen et al., 2006).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3:  Drug Metabolism (after Katzung, 2009). 
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The inhibitory effect of statins on HMG-CoA reductase also leads to deficiencies 
in other biological molecules.  One of the molecules affected by statin therapy is, 
Coenzyme Q10 (Figure 4), a ubiquitous molecule of the body, especially found in the 
heart, liver, and skeletal muscles (Balakrishnan et al., 2009).  A fat-soluble, vitamin-like 
benzoquinone compound (Nakajima et al., 2008), Coenzyme Q10 is 2, 3-dimethoxy, 5-
methyl, 6-polyisoprene parabenzoquinone (Crane, 2001).  Not only does it function as an 
energy-producing molecule in the body, but also as an antioxidant which protects cells 
from free radicals.  Coenzyme Q10 is a crucial component of the electron transport chain 
of oxidative phosphorylation that takes place in the mitochondria (see Figure 5).  It serves 
as an electron acceptor for complex I (NADH: ubiquinone oxidoreducatse) and complex 
II (succinate: ubiquinone) to complex III (CoQ-cytochrome c reductase) (Shultz, 2005).  
The reduction of the quinone (oxidized form) to quinol (reduced form) enables it to carry 
electrons and protons (Crane, 2001).   The energy released is used by complexes I, III, 
and IV to transport protons from the matrix to the intermembrane space (Shultz, 2005).  
In return, this creates an electrochemical gradient to drive complex V to form adenosine 
triphosphate ATP.  Oxidative phosphorylation is the most efficient way of producing 
adenosine triphosphate (ATP), which imparts the energy necessary for muscle 
contraction and other essential cellular functions.   Complex I and II accept electrons 
from NADH and FADH2 electron donors.  Therefore, Coenzyme Q 10 serves as a 
cofactor in the production of adenosine triphosphate (ATP) serving as an electron 
acceptor (Nakajima et al., 2009).   
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Figure 4:  Structure of Coenzyme Q10 (after Naini, 2012). 
 
 
 
Figure 5:  Diagram of the electron transport chain (ETC) and the permeability transition 
pore (PTP).  Coenzyme Q10, which is the electron acceptor for complexes I and II, plays 
a central role in the ETC (Shults, 2005; with permission of publisher).  
 
 
	   9	  
Furthermore, another biochemical function of Coenzyme Q10 is that it acts as an 
antioxidant.  It is conveniently located in all cell membranes in close proximity to the 
unsaturated lipid chains and acts as a scavenger of free radicals.  Its presence is a crucial 
defense mechanism that prolongs cell life by preventing oxidative cell damage, oxidation 
of proteins and lipids (Bentinger et al., 2010).   During the metabolism of oxygen, 
especially in the reduction of oxygen by the electron transport chain (ETC) of 
mitochondria, free radicals form and if they are not neutralized by antioxidants, then they 
damage the mitochondria.  Co Q10 primarily is in its reduced state, which enables it to 
easily donate its electrons.  Co Q10 essentially renders free radicals as harmless.   
Decreased levels of Coenzyme Q10 can lead to cardiac failure and mitochondrial 
defects, which reflects it’s importance in the electron transport chain.  HMG-CoA 
reductase is the key enzyme that catalyzes the conversion of HMG-CoA to mevalonate, 
which is an early rate-limiting step in the biosynthetic pathway of cholesterol (see Figure 
2).  In healthy cells, Coenzyme Q10 is synthesized from tyrosine (or phenylalanine) and 
mevalonate (Crane, 2001).  Acetyl-CoA initiates the reactions that comprise the 
mevalonate pathway that leads to the production of farnesyl-PP, the precursor for 
cholesterol, Coenzyme Q, dolichol and isoprenylated proteins (Bentinger, 2010).   Statin 
drugs target this rate-limiting step where it competitively intervenes with the synthesis of 
cholesterol therefore decreasing Coenzyme Q10 levels but also isoprednoids and 
dolichols (Schmitz and Langmann, 2006).  Isoprenoids partake in posttranslational 
modification of several proteins, and mitochondrial function (Davidson, 2004).  
Dolichols levels are also affected which partake in the synthesis of oligosaccaharide 
chains of glycoproteins (Schmitz and Langmann, 2006).  
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Dissolution Testing 
Dissolution testing has been employed for more than fifty years in the 
pharmaceutical industry (Ameri et al., 2011).   Dissolution rate is defined as the amount 
of substance that goes into solution per unit time under standardized conditions of liquid-
solid interface, solvent composition and temperature (ibid.).   Dissolution testing is 
performed by placing a given drug dosage form in a liquid (usually of aqueous content) 
maintained at a given temperature (usually 37°C) and agitated by various means under 
regulated conditions, followed by sample collection and analysis of the samples to 
establish the cumulative percentage of drug dissolved from the drug dosage form under 
evaluation at fixed time points.    
Dissolution is used as a tool to evaluate drug release characteristics, stability of 
formulations, monitor product consistency among batches and establish in-vitro/in-vivo 
correlation amongst drug products.  It is also a key analytical test utilized for the 
identification of the physico-chemical properties of a drug product (Ameri et al., 2011).    
In essence, dissolution testing is a valuable tool used during product development to 
develop a bioequivalent product and also becomes a routine quality control test once the 
FDA approves the product for commercial manufacturing.    Pharmaceutical companies 
have employed it as a tool in assessing or projecting bioequivalence between a branded 
drug product and it’s generic counterparts (see Figure 6).  In order for a drug product to 
be bioequivalent, the rate and extent of drug absorption from the test product has to be 
similar to the rate and extent of drug absorption from the reference drug product when 
administered at the same dose of the therapeutic ingredient under similar experimental 
conditions (ibid.).  A clinical bioequivalence study is necessary to show that the test and 
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reference drug products behave the same way in-vivo and to get approval from the FDA 
for a generic drug product.  Drug products that are therapeutically equivalent must be 
pharmaceutical equivalents (i.e. they should be the same dosage form, same strength and 
also be bioequivalent to each other).  
 
 
Figure 6:  Typical dissolution bath made up of vessels and rotating paddles.  
 
 
 
Drug absorption from a solid dosage form after oral administration depends on the 
release of the drug substance from the drug product, dissolution of the drug under 
physiological conditions and permeability of the dissolved drug across the 
	   12	  
gastrointestinal tract.  Therefore, drug release and dissolution in the physiological fluids 
of the gastrointestinal tract is a prerequisite for drug absorption.  The Food and Drug 
Administration (FDA) defines bioavailability as the rate and extent to which the active 
substances or therapeutic ingredients that make up a drug product are absorbed and 
become available in the systemic circulation (Tedeschi et al., 2009).  Furthermore, as 
discussed earlier, drug dissolution is, in many instances, the rate-limiting step to drug 
absorption, because if the drug is not released and dissolved from its dosage form in the 
physiological fluids of the gastrointestinal tract, then it will not become bio-available and  
there will be no therapeutic effect.  In essence, dissolution encompasses the course of 
action of extracting the active pharmaceutical ingredient out of its solid dosage form and 
dissolving it in the physiological fluids of the gastrointestinal tract.  The next step, 
absorption, is the process of transporting the dissolved drug substance from the 
gastrointestinal lumen into the systemic circulation.  Therefore, dissolution testing serves 
as a very good in-vitro test to mimic the release of the drug from the dosage form and its 
dissolution in the fluids of the gastrointestinal tract.  This, in turn, can be used to predict 
the rate and extent of actual in-vivo drug absorption and help in developing an in-vitro/in-
vivo correlation that can predict bioequivalence amongst different drug products.  In 
some cases, however, it might not be feasible to develop a dissolution test that will 
demonstrate a correlation between the in-vitro and in-vivo performance of a drug product 
and also predict or project a reliable comparison between similar drug dosage forms.  
The United States Pharmacopeia (USP) is the most commonly used reference that 
sets the standards for drugs and drug products.  The USP monograph for a drug product 
defines the specifications, such as assay, dissolution requirements, impurity levels, etc. 
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that a drug product has to maintain throughout its shelf life.  Only drug products that 
meet the USP monograph requirements can be designated as USP.  For example, 
Simvastatin Tablets manufactured by Merck (Zocor), Teva and Dr. Reddy’s are all 
designated as Simvastatin Tablets, USP 80 mg, meaning that they all meet the USP 
monograph requirements.  The USP monograph for most drug products includes a 
dissolution test and sets specifications for the amount of drug that has to be dissolved at a 
certain time point under certain dissolution conditions.  This value is defined as the “Q” 
value for the dissolution of the drug product and is employed as a quality control measure 
and specification for all manufactured lots of that drug product.  However, the dissolution 
tests recommended by the USP for regular release testing of lots of drug products usually 
do not have enough discriminating power to establish an in-vitro/in-vivo correlation and 
cannot be used exclusively to predict bioequivalence between different drug products of 
the same drug.   
Selection of the appropriate in-vitro conditions that simulate the in-vivo 
environment and absorption process can lead to the production of an efficacious in-
vivo/in-vitro correlation.  The development of a dissolution test is constructed upon 
several physiochemical and physiodynamic factors.  The procedure involves selecting 
parameters that are suitable, such as dissolution media, apparatus type, agitation rate and 
surfactant concentration in the dissolution medium.  Numerous factors influence drug 
dissolution including: physiochemical properties of the drug (solubility), formulation 
characteristics (coatings, inactive ingredients, manufacturing parameters) and the 
dissolution method itself (apparatus type, volume, pH of medium, agitation rate) 
(Jamzad, 2005). Surfactants, such as sodium lauryl sulfate (SLS), dissolved in the 
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dissolution medium, are commonly used for dissolution tests involving poorly water-
soluble drugs such as Simvastatin.   
The solubility of a drug largely depends on the medium in which it must dissolve. 
Simvastatin is categorized as a class II drug by the biopharmaceutics classification 
system (BCS), which implies that Simvastatin has low solubility in aqueous media but 
high permeability characteristics through the gastrointestinal mucosa.  BCS serves as a 
guide for predicting intestinal drug absorption based on solubility and permeability 
parameters.  Based on the above BCS classification for Simvastatin, drug release from 
the dosage form and its solubility in the physiological fluids of the gastrointestinal tract 
(i.e., its dissolution) are the rate- liming steps for its actual in-vivo absorption.  
Simvastatin is a crystalline compound that is a water insoluble drug and 
dissolution testing requires the use of surfactants in the dissolution medium (Rao et al., 
2010).  Surfactants are compounds that lower the surface tension at the solid-liquid 
interface between a drug particle and the dissolution media, which is a physical 
determinant of the surface area available for dissolution, and also solubilize the drug by 
forming micelles (Dressman and Reppas, 2000).   Therefore, surfactants such as SLS 
increase a drug’s solubility in solution.  In essence, surfactants are meant to mimic the 
naturally occurring surfactants found in gastric juices and bile salts that enable 
dissolution of water insoluble drugs (Shah, 1989).   
Another important factor to consider is the sink conditions of the dissolution 
media.  Sink conditions require the sustainment of a volume of dissolution media that is 
at least three times greater than the volume at the saturation solubility point of the drug 
contained in the drug delivery system being evaluated (Rohrs, 2001).  Simvastatin is 
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highly permeable because it has lipophilic characteristic that allows it to cross cellular 
membranes by passive diffusion (Hameline, 1998).   Moreover, passive diffusion of a 
lipophilic drug such as Simvastatin ensures that the drug will be extensively metabolized 
by the hepatocytes of the liver.   
The pH of the dissolution medium is another important factor in dissolution 
testing (see Figure 7).  The human body contains an inherent pH gradient along the 
gastrointestinal tract.  pH dependent dissolution from a dosage form predicts where the 
drug is most likely to dissolve within the gastrointestinal tract.   The stomach has a pH 
that ranges from 1 to 3, which is extremely acidic in order to aid in the breakdown of 
proteins.  In contrast, the duodenum of the small intestine has a pH of about 5 to 6 and 
the pH continues to increase along the length of the intestinal tract.  The small intestine’s 
increased pH levels and extremely large surface area aids in the absorption of most drugs 
and nutrients.  Variations of pH along the gastrointestinal tract can affect the drugs 
solubility, dissolution and permeability (Lu et al., 2011).   
Dissolution testing should be carried out under physiological conditions because 
this allows for interpretation of dissolution data with regard to in-vivo performance of the 
product.  Numerous factors can have a major role in affecting dissolution rates and 
percent of drug dissolved.   Dissolution conditions such as apparatus type, pH of medium, 
agitation speed, sink conditions, volume and surfactants added in the dissolution medium 
are capable of causing differences in the dissolution characteristics between drug product 
counterparts.  However, another important factor are the excipients used to make up the 
bulk of the total dosage form.   In essence, excipients are the inactive ingredients that 
constitute the formulation of the drug product aside from the active pharmaceutical 
	   16	  
ingredient.   Excipients are the preservatives, colors, coating agents, flavors, solubility 
enhancers, lubricants, binders and disintegrants that control the dissolution characteristics 
of the drug from the dosage form.  
 
 
 
 
Figure 7:  pH variation along the gastrointestinal tract (Boudinot, 2012; with permission  
of publisher).  
 
 
Generic Drugs 
A generic drug product is approved by the FDA as a therapeutic equivalent to its 
corresponding branded drug product. To be approved as therapeutically equivalent, the 
generic product has to be pharmaceutically equivalent (i.e., same dosage form, strength, 
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same route of administration, etc.) and also be bioequivalent to the branded drug product.  
In a few cases where the drugs exhibit very good solubility in the gastrointestinal fluids 
and very good permeability across the gastrointestinal mucosa, the FDA may waive the 
bioequivalence requirements for a generic drug but they still need to be pharmaceutically 
equivalent to their corresponding branded drug products.  A branded drug product is the 
original drug product formulated by pharmaceutical companies.  The Brand manufacturer 
has already discovered the active pharmaceutical ingredient (API), and has evaluated the 
therapeutic and toxicological properties of the drug.  Hence, the generic drug products 
have to be therapeutically equivalent to the branded drug. 
Overall, in order to be approved as a generic of a branded product, a generic drug 
product must be bioequivalent, and also pharmaceutically equivalent to its branded 
counterpart in terms of: active ingredient, strength, purity, safety and route of 
administration (Ameri et al., 2011).  A dissolution test plays a key role in assessing the 
bioequivalence between a generic and its branded counterpart.  If the drug products are 
bioequivalent and pharmaceutically equivalent, then they are therapeutically equivalent, 
which means that they are suitable for substitution.   
Clinical bioequivalence studies are conducted in human subjects.  The brand and 
generic drug products are dosed in the human subjects using a study design.  The blood 
samples are collected from the subjects at certain time points after the drugs are dosed.  
The blood samples are analyzed for the drug content in plasma at each time point.  The 
drug concentration in the plasma at each time point is then determined.  The drug 
concentrations obtained in all the subjects after dosing the branded product and in the 
same subjects after and dosing the generic product are compared statistically for certain 
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parameters such as Cmax, Tmax, AUC0-t and AUC0-inf.  Cmax is defined as the max plasma 
concentration of a therapeutic drug and Tmax, is defined as the time at which the drug 
reaches Cmax.  AUC is the area under the curve starting from time point 0 till the last 
sampled time.  These parameters have to be within certain limits for the generic product 
to be called bioequivalent to the branded drug product.   
When dissolution tests are conducted during product development for generic 
drug products, a dissolution profile similar to that of the brand is desired, hoping it will 
have the same profile in the human body and give blood concentrations that would be 
bioequivalent to that of the brand.  This technique works in some cases.  In other cases, 
however, even if the in-vitro drug dissolution profiles are the same, the two products can 
behave differently in the body.  Furthermore, when dissolution results are different, the 
two products may still behave the same way in the human body and be bioequivalent to 
each other.   
Once a generic product is approved, dissolution becomes a part of the testing for a 
commercial batch before it can be released to the market.  This is done to ensure that the 
drug dissolution profile of each commercial batch dissolution profile is similar to that 
obtained from the batch that is bioequivalent to the brand.  This gives comfort that the 
commercial batch is behaving exactly like the batch that was sent to the bioequivalence 
study.  Also, brand companies do dissolution tests on their products to see if their 
commercial batches are behaving like their original FDA submission batches in order to 
ensure batch-to-batch reproducibility. 
Health care professionals and consumers can be certain that the FDA approved 
generic drug products have met the same strict standards as the innovator drug.  
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Otherwise, the drug will not be put on the market.  The Current Good Manufacturing 
Practice (cGMP) regulations enforced by the FDA ensures proper design, monitoring and 
control of manufacturing processes and facilities (U.S. Drug and Food Administration, 
2009).  A generic drug is required to have the same active pharmaceutical ingredient, 
strength, route of administration, dosage form and quality.  The only varying factors are 
the inactive ingredients used, also known as excipients, in the formulation of the drug that 
regulate bioavailability, solubility, rate of drug release and that bind the drug together.  
But, in general, if a company does not comply with the cGMP regulations, the drug 
product is then considered “adulterated” under the law (U.S. Drug and Food 
Administration, 2009).   
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MATERIALS AND METHODS 
 
Summary of Experimental Design 
 Three commercial products of Simvastatin USP 80 mg Tablets, namely, the brand 
Zocor 80 mg tablets manufactured by Merck Pharmaceutical Company (i.e., "Zocor" of 
Lot No. G004118) and two FDA-approved generics of Simvastatin 80 mg tablets 
equivalent to Zocor manufactured by Teva Pharmaceuticals, Inc. (i.e., "Teva" of Lot No. 
25S032) and by Dr. Reddy's Laboratories, Ltd. (i.e., "Dr. Reddy's" or "Reddy's" of Lot 
No. C105447), were tested for their drug dissolution profiles using twelve (12) different 
dissolution conditions.  Three tablets from each product were tested each time under 
varying dissolution conditions consisting of three different dissolution media, namely, 
three aqueous solutions of 0.5% w/v of Sodium Lauryl Sulfate (i.e., "SLS") dissolved in 
Phosphate Buffer pH 7.0, Purified Water or Acetate Buffer pH 4.5, and two different 
dissolution medium volumes, namely, 500 or 900 mL per dissolution vessel (containing 
one tablet per vessel) which were maintained at 37oC and agitated using paddles rotating 
at either 35 or 50 rotations per minute (rpm). 
 During each dissolution test, one tablet of each product under evaluation was 
placed in a dissolution vessel containing a certain volume (500 or 900 mL) of one of the 
three dissolution media, maintained at 37oC and agitated at a certain paddle speed (35 or 
50 rpm).  A total of three tablets from each product were tested at each dissolution 
condition.  After starting the dissolution test, 5 mL samples of the dissolution medium 
were withdrawn at 5, 10, 20, 30 and 45 minutes of the dissolution process, filtered and 
analyzed for their drug content using High Pressure Liquid Chromatography (HPLC).  
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The drug content of each sample point for the three tablets of each product tested was 
then treated statistically to yield the Average and Standard Deviation (N=3) of the 
Cumulative Percent Drug Dissolved from each product at each dissolution time point.  
Such dissolution results, which are tabulated in Tables 1-12, were then plotted versus 
time for the three products compared in this work to obtain their dissolution profiles 
shown in Figures 9-20.   
 In addition, the 10-min, 20-min and 30-min Drug Dissolution Rates of each 
product at each dissolution condition used were calculated by converting each Average of 
Cumulative Percent Drug Dissolved (shown in Tables 1-12) to milligrams (mg) of Drug 
Dissolved by multiplying the percent ratio (e.g., 0.65 for 65% of Cumulative Percent 
Drug Dissolved) with 80 mg (i.e., the strength of each product tested), and then by 
dividing such multiplication product by 10, 20 or 30 minutes, respectively, to yield the 
Average 10-min, 20-min or 30-min Drug Dissolution Rates (in mg/min), respectively, for 
each product tested at each dissolution condition.  Similar treatment was also applied to 
the corresponding Standard Deviations (also shown in Tables 1-12) to obtain the relevant, 
corresponding Standard Deviations of the 10-min, 20-min or 30-min Drug Dissolution 
Rates (in mg/min) for each product tested at each dissolution condition.  Such Averages 
and Standard Deviations of the 10-min, 20-min and 30-min Drug Dissolution Rates of 
each product tested at each dissolution condition are tabulated in Tables 13-30 and 
plotted as bar graphs in Figures 21-38. 
 Finally, the differences between the 10-min, 20-min and 30-min Drug Dissolution 
Rates observed from the Brand Zocor Simvastatin 80 mg Tablets and the Generic Teva or 
Dr. Reddy's Simvastatin products tested in 500 or 900 mL volumes of dissolution media 
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under the different dissolution conditions used, were analyzed for statistical significance 
using hypothesis t-testing wherein the t-statistics pertaining to paired comparisons of the 
dissolution rates exhibited by Zocor vs. Teva and Zocor vs. Dr. Reddy's, were calculated 
and compared to two-sided t-distributions with 4 degrees of freedom (i.e., 4 d.f.) for 
statistical significance at P-levels smaller than 5% (i.e., P<0.05) and/or 1% (i.e., P<0.01).  
Such statistical analysis and comparison results are shown in Tables 31-42 and further 
summarized in Tables 43-45. 
 
Materials 
 The following materials were purchased and donated for the needs of this project 
by Sigmapharm Laboratories, LLC, and they were used as received: 
 1. Zocor (Simvastatin Tablets, USP 80 mg) of Lot No. G004118) manufactured by 
Merck Pharmaceutical Company (reference branded product); 
 2.   Simvastatin Tablets, USP 80 mg, of Lot No. 25S032 manufactured by Teva 
Pharmaceuticals, Inc., as the generic equivalent of the brand Zocor; 
 3.   Simvastatin Tablets, USP 80 mg, of Lot No. C105447 manufactured by Dr. Reddy’s 
Laboratories, Ltd., as the generic equivalent of the brand Zocor; 
 4. Simvastatin USP Standard, of Lot No. I1H070 manufactured by USP, Rockville, 
MD; 
 5. Sodium Lauryl Sulfate (SLS) of Lot No. S6371050141 manufactured by Merck, 
Germany; 
 6. Phosphoric Acid 85% of Lot No. 45315604 manufactured by EMD Chemicals, NJ; 
 7. Sodium Phosphate of Lot No. Lot No. 46789120 manufactured by EMD Chemicals, 
NJ; 
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 8. Monobasic Sodium Phosphate Lot No. A01131014 manufactured by EMD 
Chemicals, NJ; 
 9. Acetic Acid of Lot No. C32004 manufactured by Mallinckrodt Chemicals; 
10. Sodium Acetate of Lot No. 93454 manufactured by BDH; 
11. Sodium Hydroxide of Lot No. B0630569135 manufactured by EMD Chemicals, NJ; 
12. Acetonitrile of Lot No. 52040 manufactured by EMD Chemicals, NJ; 
13. Whatman disc filters of 0.45 µm of Lot No. 51580 manufactured by Whatman; 
14. Thermo Scientific Column, part # 30105-254630, 250 x 4.5 mm, 5 µ packing of Lot 
No. 11444 manufactured by Thermo Scientific; and 
15. Purified Water and HPLC-grade Water (produced at Sigmapharm Laboratories). 
 
Methods 
 
Dissolution Testing 
 Three commercial products of Simvastatin USP 80 mg Tablets, namely, the brand 
Zocor reference product and two FDA-approved generic products, i.e., Teva and Reddy's, 
were tested for their drug dissolution profiles using twelve different conditions.  All 
dissolution tests were performed using a United States Pharmacopeia apparatus II (paddle 
method) dissolution bath containing six vessels maintained at 37°C.  Three tablets from 
each product were tested each time under varying dissolution conditions consisting of 
three different dissolution media, namely, three aqueous solutions of 0.5% w/v of SLS in 
Phosphate Buffer pH 7.0, Purified Water or Acetate Buffer pH 4.5, and two different 
dissolution medium volumes, namely, 500 or 900 mL per dissolution vessel (containing 
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one tablet per vessel), which were maintained at 37oC and agitated using paddles rotating 
at either 35 or 50 rpm. 
 
 
Preparation of Dissolution Media 
 Each dissolution medium intended for a given dissolution test was made and used 
daily.  A 1,000 mL volumetric cylinder was used to measure 6,000 mL of Purified Water 
that was added to a large glass vessel.  A stirrer was placed in the glass vessel in order to 
mix the components thoroughly.  The glass vessel containing the Purified Water was 
placed on top of a stir plate and stirred until everything that was added became fully 
dissolved.  Depending on the dissolution test planned to be performed, one of the 
following dissolution media was prepared and used daily:  
1. Phosphate Buffer pH 7.0 with 0.5% w/v SLS, which is the dissolution medium 
recommended by USP for Simvastatin immediate release tablets (USP medium); 
2.  Purified Water with 0.5% w/v SLS; and  
3.  Acetate Buffer pH 4.5 with 0.5% w/v SLS.   
 If necessary, the USP medium’s pH was adjusted with Sodium Hydroxide, and 
the Acetate Buffer’s pH was adjusted with Phosphoric Acid.  For every liter of total 
dissolution medium, 5 grams of SLS was used to make each of the dissolution media 
containing 0.5% w/v SLS.  It should be noted that % w/v means grams of solute (e.g., 0.5 
grams of SLS) per 100 mL of solution (e.g., consisting, in this case, of SLS as the solute 
and Phosphate Buffer pH 7.0, Purified Water or Acetate Buffer pH 4.5, as the solvent).    
 The USP medium was made up of pH 7.0 Phosphate Buffer solution containing 
0.5% w/v SLS in 0.01 M Sodium Phosphate prepared by dissolving 30 grams of SLS and 
8.28 grams of Monobasic Sodium Phosphate in 6,000 mL of Purified Water, and 
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adjusting with 50% w/v of Sodium Hydroxide solution to a pH of 7.0.  The second 
dissolution medium was made up of 0.5% w/v SLS in Purified Water.    In other words, 
for each liter of the second dissolution medium, Purified Water was added to 5 grams of 
SLS to prepare a total volume of solution equal to 1,000 mL.  Lastly, the 0.5% w/v SLS 
in Acetate Buffer pH 4.5 dissolution medium was made up of 17.99 grams of Sodium 
Acetate mixed with 84 mL of 2 N Acetic Acid for every 6,000 mL made containing 30 
grams of SLS.  It should be also noted that for the USP and Acetate Buffer dissolution 
media, the pHs of the buffer solutions were always measured prior to the addition of SLS.  
 
 
Dissolution Procedure 
 During each dissolution test, one tablet of each product under evaluation was 
placed in one dissolution vessel containing a certain volume (500 or 900 mL) of one of 
the three dissolution media, maintained at 37oC and agitated at a certain paddle speed (35 
or 50 rpm).  A total of three tablets from each product were tested at each dissolution 
condition.  After starting the dissolution test, 5 mL samples of the dissolution medium 
were withdrawn at 5, 10, 20, 30 and 45 minutes of the dissolution process, filtered 
through a Whatman disc filter of 0.45 mm and analyzed for their drug content using High 
Pressure Liquid Chromatography or, as commonly referred to, HPLC analysis.  After 
each sample withdrawal, 5 mL of fresh dissolution medium was added (replaced) in each 
dissolution vessel in order to maintain the volume of the dissolution medium constant in 
each vessel.  The drug content of each sample point for the three tablets of each product 
tested was then treated statistically to yield the Average and Standard Deviation (N=3) of 
Cumulative Percent Drug Dissolved from each product at each dissolution time point.  
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Such dissolution results, which are tabulated in Tables 1-12, were then plotted versus 
time for the three products compared in this work to obtain their dissolution profiles 
shown in Figures 9-20.  It should be also noted that after collection of the 30-minute 
samples, the agitation speed of the dissolution apparatus was increased to 200 rpm for an 
additional 15 minutes in order to ensure that all drug available or able to be dissolved at 
the selected type and volume of dissolution medium was indeed fully dissolved at the end 
of each dissolution test.  Such 45-minute sample collection is also known as Recovery 
Point and is listed in the last row of Tables 1-12.  However, such 45-minute-recoveries 
are not included in the dissolution profiles plotted in Figures 9-20, since they do not 
represent actual points of drug dissolution observed under the same agitation speed 
conditions used for the preceding sample collection points.  
 
High Performance Liquid Chromatography 
High performance liquid chromatography (HPLC) was used in this study for 
sample analysis.  HPLC is a technique that can extensively separate a mixture of 
compounds from one another and is used to identify and quantify the individual 
components of the mixture (i.e., the dissolution sample in this case).  HPLC distinguishes 
the drug peak aside from all the other interferences from the dissolution medium and 
from the array of materials used to make the tablet.     
HPLC operates via a high-pressure pump to generate a particular flow rate of the 
mobile phase, then an injector injects the drug sample into the continuously flowing 
mobile phase that leads into the HPLC column.  The column is composed of 
chromatographic packing material also known as the Stationary Phase, which is needed 
	   27	  
to achieve the separation, based on binding capacities to the column.  Hence, the drug 
peak will always come out at around the same time on the chromatogram, if not, then 
something is wrong with the column, mobile phase and or HPLC conditions.  Finally, a 
detector detects the separated drug as it elutes from the HPLC which is wired to the 
computer with Empower™ 3 Software, which was used to collect, manage and identify 
the concentration of each drug sample.  
 
 
 
 
Figure 8: Components of High Performance Liquid Chromatography (©2012 Waters 
Corporation. Used with permission). 
 
 
 
Preparation of Mobile Phase and HPLC System 
Each time, four liters of mobile phase required for HPLC analysis was made and 
used daily.  The mobile phase was made up of 1,500 mL of Buffer solution of pH 4.5 
containing 5.85 grams of Monobasic Sodium Phosphate and of 2,600 mL of Acetonitrile.  
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This mobile phase solution was mixed and adjusted, if necessary, to a pH of 4.5 with 
85% w/v of Phosphoric Acid.  Once the mobile phase solution was mixed and adjusted 
for its pH, it was filtered and degassed.  Following the preparation of the mobile phase, a 
process called Wet Prime was done to fill all the tubing lines with the mobile phase so 
that there is no delay in setting up the HPLC.  This process clears all the lines of the old 
mobile phase used to run previous samples on other days.  Also, it helps in removing any 
air bubbles trapped in the lines since the lines are being flushed at a higher flow rate.  
Afterwards, a process called Monitoring was done to monitor the baseline and see if there 
were any unwanted peaks in order to ensure that the HPLC column and detector have 
been equilibrated.  Subsequently, a standard solution containing a known concentration 
of Simvastatin was injected in order to ensure that Simvastatin was in fact soluble in the 
dissolution medium being tested and that there was no interference to the drug peak 
appearing on the chromatogram.   
 
 
Preparation of Standard Simvastatin Solutions for HPLC Analysis 
Prior to running a dissolution test, a standard solution of Simvastatin in the 
pertinent dissolution medium was prepared for quantitation purposes.  The standard 
solution was prepared by dissolving the drug in sufficient volume of methanol and then 
making up the volume with the dissolution media.  When preparing a standard stock 
solution for a dissolution test involving 900 mL of dissolution medium volume, a 100 mL 
volumetric flask was used consisting of 8.8 mg of accurately weighed Simvastatin 
reference standard so that the concentration of the drug in the standard solution would 
represent the 100% dissolution level expected to be obtained.  This was determined by 
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dividing the dosage of Simvastatin per tablet (i.e., 80 mg) by the dissolution volume (i.e., 
900 mL) present in that type of dissolution testing.  On the other hand, a standard solution 
for a dissolution test involving a 500 mL dissolution medium volume was prepared in a 
50 mL volumetric flask consisting of 8.0 mg of accurately weighed Simvastatin reference 
standard.  Generally, for the Phosphate Buffer pH 7.0 with 0.5% w/v SLS and the 
Purified Water with 0.5% w/v SLS dissolution media, about 5 to 10 mL of methanol was 
required to dissolve Simvastatin in the flask.  A standard solution made from the Acetate 
Buffer pH 4.5 with 0.5% w/v SLS dissolution medium required anywhere between 20 to 
40 mL of methanol to fully dissolve Simvastatin since this drug is not freely soluble in 
the Acetate Buffer system.  
 
 
Procedure for HPLC Analysis of Dissolution Samples 
Generally, all samples were run for 20 minutes after a 10 µL injection was made 
for each sample.  After all dissolution samples were collected and filtered directly into 
HPLC vials, they were placed in a sample tray and were each analyzed individually for 
their drug content by being injected into the prepared HPLC system consisting of the 
mobile phase, namely, a degassed mixture of acetonitrile and buffer solution of pH 4.5 
(650:350 v/v), flowing through the HPLC column at a flow rate of 1.5 mL/min.  The 
HPLC column used was a Thermo Scientific Column, part # 30105-254630, 250 x 4.5 
mm (lot # 11444) with 5 µ packing, which was maintained at a temperature of 45°C.  The 
HPLC system was also equipped with a UV detector operating at a wavelength λmax of 
238 nm, which is the wavelength of maximum absorbance for Simvastatin.   
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After a 10 mL injection of each filtered dissolution sample was run through the 
HPLC system for a run time of 20 minutes, a chromatogram (see Figure 8a) was 
produced showing the peak of the drug at about 9.5 minutes (retention time).  The area of 
the chromatographic Simvastatin peak produced by each dissolution sample (i.e., "sample 
area") was then compared to that of the pertinent standard Simvastatin solution 
representing the 100% dissolution level for the relevant dissolution test and dissolution 
medium volume discussed previously ("std area").  To process the data obtained by 
HPLC analysis, the factor component of the Percent Drug Dissolved formula was 
calculated and entered into the Empower Software to calculate via the sample's and 
standard's drug areas under the curve the actual Cumulative Percent of Drug Dissolved at 
each dissolution time point.   
In essence, the Cumulative Percent Drug Dissolved is equal to (sample area/Std 
area) x (wt of std/stock vol) x (C/100) x (dissolution media vol/label claim) x 100.  The 
software calculates the sample area divided by the standard area and the factor depending 
upon the dissolution medium volume was calculated by hand.  The letter C in the formula 
is the purity of the standard which, in this project and for the Simvastatin reference 
standard used, is equal to 100%, label claim is the drug strength per tablet which is equal 
to 80 mg, and the standard volume and weight varies with the volume of dissolution 
medium used for the specific dissolution test.  
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Figure 8a:  Chromatogram of Simvastatin using this study's HPLC system (©2012 
Waters Corporation. Used with permission). 
 
 
 
 
Calculation of Drug Dissolution Rates 
 The 10-min, 20-min and 30-min Drug Dissolution Rates of each product at each 
dissolution condition used were calculated by converting each Average of Cumulative 
Percent Drug Dissolved (shown in Tables 1-12) to milligrams (mg) of Drug Dissolved by 
multiplying the percent ratio (e.g., 0.65 for 65% of Cumulative Percent Drug Dissolved) 
with 80 mg (i.e., the strength of each product tested), and then by dividing such 
multiplication product by 10, 20 or 30 minutes, respectively, to yield the Average 10-
min, 20-min or 30-min Drug Dissolution Rates (in mg/min), respectively, for each 
product tested at each dissolution condition.  Similar treatment was also applied to the 
corresponding Standard Deviations (also shown in Tables 1-12) to obtain the relevant, 
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corresponding Standard Deviations of the 10-min, 20-min or 30-min Drug Dissolution 
Rates (in mg/min) for each product tested at each dissolution condition.  Such Averages 
and Standard Deviations of the 10-min, 20-min and 30-min Drug Dissolution Rates of 
each product tested at each dissolution condition are tabulated in Tables 13-30 and 
plotted as bar graphs in Figures 21-38. 
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RESULTS AND DISCUSSION 
Dissolution Profiles 
The results of dissolution testing conducted under twelve different conditions 
(i.e., 12 combinations of three different dissolution media and two different dissolution 
volumes and agitation speeds) on the three commercial Simvastatin products under 
evaluation are tabulated in Tables 1-12 as Averages of Cumulative Percent Drug 
Dissolved from three tablets of each product (i.e., N=3), along with their corresponding 
Standard Deviations (given in parentheses), observed at each time point of dissolution 
sample collection.  In addition, such dissolution results are plotted versus time (minutes) 
of sample collection in Figures 9-20 to display the dissolution profiles of the three tested 
Simvastatin products exhibited at such twelve dissolution conditions.   
It should be also noted that after collection of the 30-minute samples, the agitation 
speed of the dissolution apparatus was increased to 200 rotations per minute (rpm) for an 
additional 15 minutes in order to ensure that all drug available or able to be dissolved at 
the selected type and volume of dissolution medium was indeed fully dissolved at the end 
of each dissolution test.  Such 45-minute sample collection is also known as Recovery 
Point and is presented in the last row of Tables 1-12 below.  However, such 45-minute-
recoveries are not included in the dissolution profiles plotted in Figures 9-20, since they 
do not represent actual points of drug dissolution observed under the same agitation 
speed conditions used for the preceding sample collection points. 
As shown in Figures 9-20, various dissolution conditions produced dissolution 
profiles of the three Simvastatin products possessing varying degrees of similarities or 
differences amongst them, as seen in the Discussion section below. 
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Table 1: Cumulative Percent Drug Dissolved from 3 commercial products of Simvastatin 
Tablets, USP 80 mg (Zocor: lot# G004118, Teva: lot# 25S032 and Dr. Reddy's: lot# 
C105447) in 500 mL (per tablet) of an aqueous medium containing 0.5% w/v of SLS in 
Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37°C and agitated by 
paddles rotating at 35 rpm.  The Averages of Cumulative-Percent-Drug-Dissolved from three tablets 
of each product are reported along with their corresponding Standard Deviations (given in parentheses). 
  
Time (min) Zocor Tablets 
(G004118) 
Teva Tablets 
(25S032) 
Dr. Reddy's Tablets 
(C105447) 
0 0% 0% 0% 
5 2% (1.5) 32% (5.2) 74% (15) 
10 39% (8.9) 60% (2.5) 83% (9.8) 
20 79% (6.6) 80% (2.1) 90% (6.2) 
30 86% (3.1) 86% (1.0) 93% (5.0) 
45 (recovery) 94% (0.6) 95% (0.0) 98% (0.6) 
 
 
Figure 9:  Dissolution Profiles of 3 commercial products of Simvastatin Tablets, USP 80 
mg (Zocor, Teva and Dr. Reddy's) obtained in 500 mL (per tablet) of an aqueous medium 
containing 0.5% w/v of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium) 
maintained at 37°C and agitated by paddles rotating at 35 rpm.  (Each point is the Average of 
the Cumulative-Percent-Drug-Dissolved from three tablets, and error-bars are the Standard Deviations) 
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Table 2: Cumulative Percent Drug Dissolved from 3 commercial products of Simvastatin 
Tablets, USP 80 mg (Zocor: lot# G004118, Teva: lot# 25S032 and Dr. Reddy's: lot# 
C105447) in 500 mL (per tablet) of an aqueous medium containing 0.5% w/v of SLS in 
Purified Water maintained at 37°C and agitated by paddles rotating at 35 rpm.   
The Averages of Cumulative-Percent-Drug-Dissolved from three tablets (N=3) of each product are 
reported along with their corresponding Standard Deviations, which are given in parentheses. 
  
Time (min) Zocor Tablets 
(G004118) 
Teva Tablets 
(25S032) 
Dr. Reddy's Tablets 
(C105447) 
0 0% 0% 0% 
5 4% (2.0) 33% (6.6) 35% (9.6) 
10 44% (9.5) 59% (1.0) 58% (5.5) 
20 62% (2.6) 63% (1.5) 68% (0.0) 
30 64% (2.1) 64% (1.2) 71% (3.2) 
45 (recovery) 63% (1.2) 64% (0.6) 71% (1.5) 
 
 
Figure 10:  Dissolution Profiles of three commercial products of Simvastatin Tablets, 
USP 80 mg (Zocor, Teva and Dr. Reddy's) obtained in 500 mL (per tablet) of an aqueous 
medium containing 0.5% w/v of SLS in Purified Water maintained at 37°C and agitated 
by paddles rotating at 35 rpm.  (Each point represents the Average of the Cumulative-Percent-Drug-
Dissolved from three tablets, and error-bars represent the corresponding Standard Deviations) 
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Table 3: Cumulative Percent Drug Dissolved from 3 commercial products of Simvastatin 
Tablets, USP 80 mg (Zocor: lot# G004118, Teva: lot# 25S032 and Dr. Reddy's: lot# 
C105447) in 500 mL (per tablet) of an aqueous medium containing 0.5% w/v of SLS in 
Acetate Buffer pH 4.5 maintained at 37°C and agitated by paddles rotating at 35 rpm.   
The Averages of Cumulative-Percent-Drug-Dissolved from three tablets (N=3) of each product are 
reported along with their corresponding Standard Deviations which are given in parentheses. 
  
Time (min) Zocor Tablets 
(G004118) 
Teva Tablets 
(25S032) 
Dr. Reddy's Tablets 
(C105447) 
0 0% 0% 0% 
5 6% (7.0) 35% (7.6) 23% (8.3) 
10 34% (17.2) 66% (7.5) 46% (5.2) 
20 69% (2.6) 75% (2.5) 60% (8.5) 
30 73% (0.6) 76% (1.0) 62% (7.0) 
45 (recovery) 81% (1.2) 80% (0.6) 73% (7.5) 
 
 
Figure 11:  Dissolution Profiles of three commercial products of Simvastatin Tablets, 
USP 80 mg (Zocor, Teva and Dr. Reddy's) in 500 mL (per tablet) of an aqueous medium 
containing 0.5% w/v of SLS in Acetate Buffer pH 4.5 maintained at 37°C and agitated 
by paddles rotating at 35 rpm.  (Each point represents the Average of the Cumulative-Percent-Drug-
Dissolved from three tablets, and error-bars represent the corresponding Standard Deviations) 
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Table 4: Cumulative Percent Drug Dissolved from 3 commercial products of Simvastatin 
Tablets, USP 80 mg (Zocor: lot# G004118, Teva: lot# 25S032 and Dr. Reddy's: lot# 
C105447) in 500 mL (per tablet) of an aqueous medium containing 0.5% w/v of SLS in 
Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37°C and agitated by 
paddles rotating at 50 rpm.  The Averages of Cumulative-Percent-Drug-Dissolved from three tablets 
of each product are reported along with their corresponding Standard Deviations (given in parentheses). 
  
Time (min) Zocor Tablets 
(G004118) 
Teva Tablets 
(25S032) 
Dr. Reddy's Tablets 
(C105447) 
0 0% 0% 0% 
5 12% (8.3) 60% (10.5) 61% (6.9) 
10 64% (5.5) 86% (5.3) 86% (1.5) 
20 90% (0.0) 91% (3.1) 94% (2.1) 
30 93% (0.6) 92% (2.5) 95% (2.1) 
45 (recovery) 95% (0.6) 94% (1.5) 96% (1.2) 
 
 
Figure 12: Dissolution Profiles of 3 commercial products of Simvastatin Tablets, USP 80 
mg (Zocor, Teva and Dr. Reddy's) obtained in 500 mL (per tablet) of an aqueous medium 
containing 0.5% w/v of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium) 
maintained at 37°C and agitated by paddles rotating at 50 rpm.  (Each point is the Average of 
the Cumulative-Percent-Drug-Dissolved from three tablets, and error-bars are the Standard Deviations) 
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Table 5: Cumulative Percent Drug Dissolved from 3 commercial products of Simvastatin 
Tablets, USP 80 mg (Zocor: lot# G004118, Teva: lot# 25S032 and Dr. Reddy's: lot# 
C105447) in 500 mL (per tablet) of an aqueous medium containing 0.5% w/v of SLS in 
Purified Water maintained at 37°C and agitated by paddles rotating at 50 rpm.   
The Averages of Cumulative-Percent-Drug-Dissolved from three tablets (N=3) of each product are 
reported along with their corresponding Standard Deviations which are given in parentheses. 
  
Time (min) Zocor Tablets 
(G004118) 
Teva Tablets 
(25S032) 
Dr. Reddy's Tablets 
(C105447) 
0 0% 0% 0% 
5 24% (15.3) 50% (16.3) 47% (13.2) 
10 75% (4.2) 80% (2.1) 69% (3.5) 
20 83% (1.0) 84% (2.0) 72% (1.0) 
30 80% (1.7) 84% (0.6) 70% (1.5) 
45 (recovery) 78% (1.0) 84% (3.1) 67% (1.0) 
 
 
Figure 13:  Dissolution Profiles of three commercial products of Simvastatin Tablets, 
USP 80 mg (Zocor, Teva and Dr. Reddy's) obtained in 500 mL (per tablet) of an aqueous 
medium containing 0.5% w/v of SLS in Purified Water maintained at 37°C and agitated 
by paddles rotating at 50 rpm.  (Each point represents the Average of the Cumulative-Percent-Drug-
Dissolved from three tablets, and error-bars represent the corresponding Standard Deviations)  
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Table 6: Cumulative Percent Drug Dissolved from 3 commercial products of Simvastatin 
Tablets, USP 80 mg (Zocor: lot# G004118, Teva: lot# 25S032 and Dr. Reddy's: lot# 
C105447) in 500 mL (per tablet) of an aqueous medium containing 0.5% w/v of SLS in 
Acetate Buffer pH 4.5 maintained at 37°C and agitated by paddles rotating at 50 rpm.   
The Averages of Cumulative-Percent-Drug-Dissolved from three tablets (N=3) of each product are 
reported along with their corresponding Standard Deviations which are given in parentheses. 
  
Time (min) Zocor Tablets 
(G004118) 
Teva Tablets 
(25S032) 
Dr. Reddy's Tablets 
(C105447) 
0 0% 0% 0% 
5 37% (1.2) 73% (4.7) 36% (13.1) 
10 78% (3.2) 82% (2.6) 68% (3.0) 
20 87% (0.6) 83% (1.5) 79% (0.6) 
30 85% (1.0) 82% (0.6) 81% (0.0) 
45 (recovery) 83% (1.5) 82% (1.0) 82% (0.6) 
 
 
Figure 14:  Dissolution Profiles of three commercial products of Simvastatin Tablets, 
USP 80 mg (Zocor, Teva and Dr. Reddy's) in 500 mL (per tablet) of an aqueous medium 
containing 0.5% w/v of SLS in Acetate Buffer pH 4.5 maintained at 37°C and agitated 
by paddles rotating at 50 rpm. (Each point represents the Average of the Cumulative-Percent-Drug-
Dissolved from three tablets, and error-bars represent the corresponding Standard Deviations) 
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Table 7: Cumulative Percent Drug Dissolved from 3 commercial products of Simvastatin 
Tablets, USP 80 mg (Zocor: lot# G004118, Teva: lot# 25S032 and Dr. Reddy's: lot# 
C105447) in 900 mL (per tablet) of an aqueous medium containing 0.5% w/v of SLS in 
Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37°C and agitated by 
paddles rotating at 35 rpm.  The Averages of Cumulative-Percent-Drug-Dissolved from three tablets 
of each product are reported along with their corresponding Standard Deviations (given in parentheses). 
  
Time (min) Zocor Tablets 
(G004118) 
Teva Tablets 
(25S032) 
Dr. Reddy's Tablets 
(C105447) 
0 0% 0% 0% 
5 6% (2.0) 21% (17.0) 18% (0.6) 
10 44% (19.3) 49% (15.8) 50% (9.0) 
20 79% (3.0) 79% (8.7) 79% (4.2) 
30 89% (1.0) 86% (5.5) 88% (1.2) 
45 (recovery) 96% (0.6) 95% (0.0) 99% (1.2) 
 
 
Figure 15: Dissolution Profiles of 3 commercial products of Simvastatin Tablets, USP 80 
mg (Zocor, Teva and Dr. Reddy's) obtained in 900 mL (per tablet) of an aqueous medium 
containing 0.5% w/v of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium) 
maintained at 37°C and agitated by paddles rotating at 35 rpm.  (Each point is the Average of 
the Cumulative-Percent-Drug-Dissolved from three tablets, and error-bars are the Standard Deviations) 
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Table 8: Cumulative Percent Drug Dissolved from 3 commercial products of Simvastatin 
Tablets, USP 80 mg (Zocor: lot# G004118, Teva: lot# 25S032 and Dr. Reddy's: lot# 
C105447) in 900 mL (per tablet) of an aqueous medium containing 0.5% w/v of SLS in 
Purified Water maintained at 37°C and agitated by paddles rotating at 35 rpm.   
The Averages of Cumulative-Percent-Drug-Dissolved from three tablets (N=3) of each product are 
reported along with their corresponding Standard Deviations which are given in parentheses. 
  
Time (min) Zocor Tablets 
(G004118) 
Teva Tablets 
(25S032) 
Dr. Reddy's Tablets 
(C105447) 
0 0% 0% 0% 
5 6% (3.1) 40% (1.0) 34% (3.1) 
10 47% (9.6) 69% (4.7) 63% (4.7) 
20 76% (2.6) 83% (2.1) 85% (4.0) 
30 81% (1.5) 82% (2.0) 89% (2.0) 
45 (recovery) 80% (1.0) 82% (1.0) 92% (1.0) 
 
 
Figure 16:  Dissolution Profiles of three commercial products of Simvastatin Tablets, 
USP 80 mg (Zocor, Teva and Dr. Reddy's) obtained in 900 mL (per tablet) of an aqueous 
medium containing 0.5% w/v of SLS in Purified Water maintained at 37°C and agitated 
by paddles rotating at 35 rpm.  (Each point represents the Average of the Cumulative-Percent-Drug-
Dissolved from three tablets, and error-bars represent the corresponding Standard Deviations) 
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Table 9: Cumulative Percent Drug Dissolved from 3 commercial products of Simvastatin 
Tablets, USP 80 mg (Zocor: lot# G004118, Teva: lot# 25S032 and Dr. Reddy's: lot# 
C105447) in 900 mL (per tablet) of an aqueous medium containing 0.5% w/v of SLS in 
Acetate Buffer pH 4.5 maintained at 37°C and agitated by paddles rotating at 35 rpm.   
The Averages of Cumulative-Percent-Drug-Dissolved from three tablets (N=3) of each product are 
reported along with their corresponding Standard Deviations which are given in parentheses. 
  
Time (min) Zocor Tablets 
(G004118) 
Teva Tablets 
(25S032) 
Dr. Reddy's Tablets 
(C105447) 
0 0% 0% 0% 
5 7% (6.4) 36% (13.5) 27% (6.0) 
10 34% (15.7) 58% (14.3) 55% (6.1) 
20 67% (4.7) 73% (6.7) 71% (2.6) 
30 73% (2.6) 74% (2.0) 76% (1.5) 
45 (recovery) 77% (0.6) 77% (1.0) 81% (1.2) 
 
 
Figure 17: Dissolution results obtained from three commercial products of Simvastatin 
Tablets, USP 80 mg (Zocor: lot# G004118, Teva: lot# 25S032 and Dr. Reddy's: lot# 
C105447) in 900 mL (per tablet) of an aqueous medium containing 0.5% w/v of SLS in 
Acetate Buffer pH 4.5 maintained at 37°C and agitated by paddles rotating at 35 rpm. 
(Each point represents the Average of the Cumulative-Percent-Drug-Dissolved from three tablets, and 
error-bars represent the corresponding Standard Deviations) 
 
	   43	  
Table 10: Cumulative Percent Drug Dissolved from 3 marketed products of Simvastatin 
Tablets, USP 80 mg (Zocor: lot# G004118, Teva: lot# 25S032 and Dr. Reddy's: lot# 
C105447) in 900 mL (per tablet) of an aqueous medium containing 0.5% w/v of SLS in 
Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37°C and agitated by 
paddles rotating at 50 rpm.  The Averages of Cumulative-Percent-Drug-Dissolved from three tablets 
of each product are reported along with their corresponding Standard Deviations (given in parentheses). 
  
Time (min) Zocor Tablets 
(G004118) 
Teva Tablets 
(25S032) 
Dr. Reddy's Tablets 
(C105447) 
0 0% 0% 0% 
5 9% (3.5) 62% (7.5) 53% (0.6) 
10 76% (9.1) 89% (2.5) 92% (2.6) 
20 95% (0.6) 98% (2.6) 100% (1.5) 
30 96% (1.2) 98% (2.5) 102% (1.0) 
45 (recovery) 97% (1.2) 99% (2.1) 103% (1.0) 
 
 
Figure 18: Dissolution Profiles of 3 commercial products of Simvastatin Tablets, USP 80 
mg (Zocor, Teva and Dr. Reddy's) obtained in 900 mL (per tablet) of an aqueous medium 
containing 0.5% w/v of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium) 
maintained at 37°C and agitated by paddles rotating at 50 rpm.  (Each point is the Average of 
the Cumulative-Percent-Drug-Dissolved from three tablets, and error-bars are the Standard Deviations) 
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Table 11: Cumulative Percent Drug Dissolved from 3 marketed products of Simvastatin 
Tablets, USP 80 mg (Zocor: lot# G004118, Teva: lot# 25S032 and Dr. Reddy's: lot# 
C105447) in 900 mL (per tablet) of an aqueous medium containing 0.5% w/v of SLS in 
Purified Water maintained at 37°C and agitated by paddles rotating at 50 rpm.   
The Averages of Cumulative-Percent-Drug-Dissolved from three tablets (N=3) of each product are 
reported along with their corresponding Standard Deviations which are given in parentheses. 
  
Time (min) Zocor Tablets 
(G004118) 
Teva Tablets 
(25S032) 
Dr. Reddy's Tablets 
(C105447) 
0 0% 0% 0% 
5 8% (4.6) 29% (25.7) 67% (0.6) 
10 55% (15.7) 78% (3.6) 97% (1.5) 
20 85% (1.0) 83% (3.2) 102% (0.0) 
30 85% (0.6) 89% (2.6) 101% (1.0) 
45 (recovery) 86% (1.5) 87% (0.6) 101% (1.5) 
 
 
Figure 19:  Dissolution Profiles of three commercial products of Simvastatin Tablets, 
USP 80 mg (Zocor, Teva and Dr. Reddy's) obtained in 900 mL (per tablet) of an aqueous 
medium containing 0.5% w/v of SLS in Purified Water maintained at 37°C and agitated 
by paddles rotating at 50 rpm.  (Each point represents the Average of the Cumulative-Percent-Drug-
Dissolved from three tablets, and error-bars represent the corresponding Standard Deviations) 
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Table 12: Cumulative Percent Drug Dissolved from 3 marketed products of Simvastatin 
Tablets, USP 80 mg (Zocor: lot# G004118, Teva: lot# 25S032 and Dr. Reddy's: lot# 
C105447) in 900 mL (per tablet) of an aqueous medium containing 0.5% w/v of SLS in 
Acetate Buffer pH 4.5 maintained at 37°C and agitated by paddles rotating at 50 rpm.   
The Averages of Cumulative-Percent-Drug-Dissolved from three tablets (N=3) of each product are 
reported along with their corresponding Standard Deviations which are given in parentheses. 
  
Time (min) Zocor Tablets 
(G004118) 
Teva Tablets 
(25S032) 
Dr. Reddy's Tablets 
(C105447) 
0 0% 0% 0% 
5 11% (7.8) 50% (10.5) 55% (2.6) 
10 69% (4.6) 75% (1.5) 76% (1.2) 
20 80% (1.5) 79% (1.0) 83% (2.1) 
30 78% (0.0) 77% (1.0) 82% (1.0) 
45 (recovery) 76% (0.0) 76% (1.0) 82% (1.2) 
 
 
Figure 20: Dissolution results obtained from three commercial products of Simvastatin 
Tablets, USP 80 mg (Zocor: lot# G004118, Teva: lot# 25S032 and Dr. Reddy's: lot# 
C105447) in 900 mL (per tablet) of an aqueous medium containing 0.5% w/v of SLS in 
Acetate Buffer pH 4.5 maintained at 37°C and agitated by paddles rotating at 50 rpm. 
(Each point represents the Average of the Cumulative-Percent-Drug-Dissolved from three tablets, and 
error-bars represent the corresponding Standard Deviations) 
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Dissolution Rates 
The 10-min, 20-min and 30-min drug dissolution rates observed from the three 
commercial Simvastatin products tested in 500 or 900 mL volumes of dissolution media 
under the different dissolution conditions used, are tabulated in Tables 13-30 as Averages 
of Cumulative Amount Drug Dissolved per Minute (in mg/min) from three tablets of 
each product (i.e., N=3), along with their corresponding Standard Deviations (given in 
parentheses), within the first 10, 20 and 30 minutes, respectively, of the dissolution 
process.  Such drug dissolution rates are calculated from the Averages of Cumulative 
Percent Drug Dissolved at the relevant time points, i.e., at 10, 20 or 30 minutes of 
dissolution (listed previously in Tables 1-12), by dividing such averages (expressed in %) 
by 100, then multiplying the results by 80 mg and then dividing the products by 10, 20 or 
30 minutes, respectively, to find the 10-min, 20-min or 30-min drug dissolution rates, 
respectively, in mg/min.  Similar treatment of the corresponding Standard Deviation 
percents of drug dissolved reported also for the same time points in Tables 1-12, yield the 
Standard Deviations of such drug dissolution rates which are also listed in Tables 13-30.  
In addition, such 10-min, 20-min and 30-min drug dissolution rates observed from 
each of the three commercial Simvastatin products tested in 500 mL or 900 mL volumes 
of pertinent dissolution medium and agitation speed, are also compared in the bar graphs 
of Figures 21-38.  As shown in Figures 21-38 and well in agreement with comparisons of 
the dissolution profiles previously shown in Figures 9-20, various dissolution conditions 
resulted in 10-min, 20-min and 30-min drug dissolution rates of the three commercial 
Simvastatin products possessing varying degrees of similarities or differences amongst 
them, which are further compared and explained in the Discussion section below. 
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Table 13: Drug Dissolution Rates displayed by three commercial products of Simvastatin 
Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 10-Minutes of their 
dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 0.5% w/v 
of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37oC and 
agitated by paddles rotating at 35 rpm.  
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along 
with their corresponding Standard Deviations which are given in parentheses. 
  
Volume of 
Dissolution 
Medium 
Zocor Tablets 
(G004118) 
mg/min 
Teva 
(25S032) 
mg/min 
Dr. Reddy's 
(C105447) 
mg/min 
500 mL 3.12 (0.71) 4.80 (0.20) 6.64 (0.78) 
900 mL 3.52 (1.54) 3.92 (1.26) 4.00 (0.72) 
 
 
Figure 21:  Drug Dissolution Rates displayed by 3 commercial products of Simvastatin 
Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 10-Minutes of their 
dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 0.5% w/v 
of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37oC and 
agitated by paddles rotating at 35 rpm.  
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Table 14: Drug Dissolution Rates (mg/min) displayed by three commercial products of 
Simvastatin Tablets, USP 80 mg (Zocor-lot#G004118, Teva-lot#25S032 and Dr.Reddy's-
lot#C105447) within the first 10-Minutes of their dissolution in 500 mL or 900 mL (per 
tablet) of an aqueous medium containing 0.5% w/v of SLS in Purified Water maintained 
at 37oC and agitated by paddles rotating at 35 rpm.   
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along 
with their corresponding Standard Deviations (given in parentheses).  
 
Volume of 
Dissolution 
Medium 
Zocor Tablets 
(G004118) 
mg/min 
Teva 
(25S032) 
mg/min 
Dr. Reddy's 
(C105447) 
mg/min 
500 mL 3.52 (0.76) 4.72 (0.08) 4.64 (0.44) 
900 mL 3.76 (0.77) 5.52 (0.38) 5.04 (0.38) 
 
 
 
Figure 22:  Drug Dissolution Rates (mg/min) displayed by three commercial products of 
Simvastatin Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 10-
Minutes of their dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium 
containing 0.5% w/v of SLS in Purified Water maintained at 37oC and agitated by 
paddles rotating at 35 rpm.    
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Table 15: Drug Dissolution Rates (mg/min) displayed by three commercial products of 
Simvastatin Tablets, USP 80 mg (Zocor-lot#G004118, Teva-lot#25S032 and Dr.Reddy's-
lot#C105447) within the first 10-Minutes of their dissolution in 500 mL or 900 mL (per 
tablet) of an aqueous medium containing 0.5% w/v of SLS in Acetate Buffer pH 4.5 
maintained at 37oC and agitated by paddles rotating at 35 rpm.  
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along 
with their corresponding Standard Deviations (given in parentheses).  
 
Volume of 
Dissolution 
Medium 
Zocor Tablets 
(G004118) 
mg/min 
Teva 
(25S032) 
mg/min 
Dr. Reddy's 
(C105447) 
mg/min 
500 mL 2.72 (1.38) 5.28 (0.60) 3.68 (0.42) 
900 mL 2.72 (1.26) 4.64 (1.14) 4.40 (0.49) 
 
 
Figure 23:  Drug Dissolution Rates (mg/min) displayed by three commercial products of 
Simvastatin Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the 10-Minutes of 
their dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 
0.5% w/v of SLS in Acetate Buffer pH 4.5 maintained at 37oC and agitated by paddles 
rotating at 35 rpm.   
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Table 16: Drug Dissolution Rates displayed by three commercial products of Simvastatin 
Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 10-Minutes of their 
dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 0.5% w/v 
of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37oC and 
agitated by paddles rotating at 50 rpm.  
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along 
with their corresponding Standard Deviations which are given in parentheses. 
 
Volume of 
Dissolution 
Medium 
Zocor Tablets 
(G004118) 
mg/min 
Teva 
(25S032) 
mg/min 
Dr. Reddy's 
(C105447) 
mg/min 
500 mL 5.12 (0.44) 6.88 (0.42) 6.88 (0.12) 
900 mL 6.08 (0.73) 7.12 (0.20) 7.36 (0.21) 
 
 
Figure 24:  Drug Dissolution Rates displayed by 3 commercial products of Simvastatin 
Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 10-Minutes of their 
dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 0.5% w/v 
of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37oC and 
agitated by paddles rotating at 50 rpm.  
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Table 17: Drug Dissolution Rates (mg/min) displayed by three commercial products of 
Simvastatin Tablets, USP 80 mg (Zocor-lot#G004118, Teva-lot#25S032 and Dr.Reddy's-
lot#C105447) within the first 10-Minutes of their dissolution in 500 mL or 900 mL (per 
tablet) of an aqueous medium containing 0.5% w/v of SLS in Purified Water maintained 
at 37oC and agitated by paddles rotating at 50 rpm.   
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along 
with their corresponding Standard Deviations (given in parentheses).  
 
Volume of 
Dissolution 
Medium 
Zocor Tablets 
(G004118) 
mg/min 
Teva 
(25S032) 
mg/min 
Dr. Reddy's 
(C105447) 
mg/min 
500 mL 6.00 (0.34) 6.40 (0.17) 5.52 (0.28) 
900 mL 4.40 (1.26) 6.24 (0.29) 7.76 (0.12) 
 
 
Figure 25:  Drug Dissolution Rates (mg/min) displayed by three commercial products of 
Simvastatin Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 10-
Minutes of their dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium 
containing 0.5% w/v of SLS in Purified Water maintained at 37oC and agitated by 
paddles rotating at 50 rpm.    
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Table 18: Drug Dissolution Rates (mg/min) displayed by three commercial products of 
Simvastatin Tablets, USP 80 mg (Zocor-lot#G004118, Teva-lot#25S032 and Dr.Reddy's-
lot#C105447) within the first 10-Minutes of their dissolution in 500 mL or 900 mL (per 
tablet) of an aqueous medium containing 0.5% w/v of SLS in Acetate Buffer pH 4.5 
maintained at 37oC and agitated by paddles rotating at 50 rpm.  
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along 
with their corresponding Standard Deviations (given in parentheses).  
 
Volume of 
Dissolution 
Medium 
Zocor Tablets 
(G004118) 
mg/min 
Teva 
(25S032) 
mg/min 
Dr. Reddy's 
(C105447) 
mg/min 
500 mL 6.24 (0.26) 6.56 (0.21) 5.44 (0.24) 
900 mL 5.52 (0.37) 6.00 (0.12) 6.08 (0.10) 
 
 
Figure 26:  Drug Dissolution Rates (mg/min) displayed by three commercial products of 
Simvastatin Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the 10-Minutes of 
their dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 
0.5% w/v of SLS in Acetate Buffer pH 4.5 maintained at 37oC and agitated by paddles 
rotating at 50 rpm.   
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Table 19: Drug Dissolution Rates displayed by three commercial products of Simvastatin 
Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 20-Minutes of their 
dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 0.5% w/v 
of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37oC and 
agitated by paddles rotating at 35 rpm.  
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along 
with their corresponding Standard Deviations which are given in parentheses. 
 
Volume of 
Dissolution 
Medium 
Zocor Tablets 
(G004118) 
mg/min 
Teva 
(25S032) 
mg/min 
Dr. Reddy's 
(C105447) 
mg/min 
500 mL 3.16 (0.26) 3.20 (0.08) 3.60 (0.25) 
900 mL 3.16 (0.12) 3.16 (0.35) 3.16 (0.17) 
 
 
 
 
 
Figure 27:  Drug Dissolution Rates displayed by 3 commercial products of Simvastatin 
Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 20-Minutes of their 
dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 0.5% w/v 
of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37oC and 
agitated by paddles rotating at 35 rpm.  
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Table 20: Drug Dissolution Rates (mg/min) displayed by three commercial products of 
Simvastatin Tablets, USP 80 mg (Zocor-lot#G004118, Teva-lot#25S032 and Dr.Reddy's-
lot#C105447) within the first 20-Minutes of their dissolution in 500 mL or 900 mL (per 
tablet) of an aqueous medium containing 0.5% w/v of SLS in Purified Water maintained 
at 37oC and agitated by paddles rotating at 35 rpm.   
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along 
with their corresponding Standard Deviations (given in parentheses).  
 
Volume of 
Dissolution 
Medium 
Zocor Tablets 
(G004118) 
mg/min 
Teva 
(25S032) 
mg/min 
Dr. Reddy's 
(C105447) 
mg/min 
500 mL 2.48 (0.10) 2.52 (0.06) 2.72 (0.00) 
900 mL 3.04 (0.10) 3.32 (0.08) 3.40 (0.16) 
 
 
Figure 28:  Drug Dissolution Rates (mg/min) displayed by three commercial products of 
Simvastatin Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 20-
Minutes of their dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium 
containing 0.5% w/v of SLS in Purified Water maintained at 37oC and agitated by 
paddles rotating at 35 rpm.    
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Table 21: Drug Dissolution Rates (mg/min) displayed by three commercial products of 
Simvastatin Tablets, USP 80 mg (Zocor-lot#G004118, Teva-lot#25S032 and Dr.Reddy's-
lot#C105447) within the first 20-Minutes of their dissolution in 500 mL or 900 mL (per 
tablet) of an aqueous medium containing 0.5% w/v of SLS in Acetate Buffer pH 4.5 
maintained at 37oC and agitated by paddles rotating at 35 rpm.  
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along 
with their corresponding Standard Deviations (given in parentheses).  
 
Volume of 
Dissolution 
Medium 
Zocor Tablets 
(G004118) 
mg/min 
Teva 
(25S032) 
mg/min 
Dr. Reddy's 
(C105447) 
mg/min 
500 mL 2.76 (0.10) 3.00 (0.10) 2.40 (0.34) 
900 mL 2.68 (0.19) 2.92 (0.27) 2.84 (0.10) 
 
 
Figure 29:  Drug Dissolution Rates (mg/min) displayed by three commercial products of 
Simvastatin Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the 20-Minutes of 
their dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 
0.5% w/v of SLS in Acetate Buffer pH 4.5 maintained at 37oC and agitated by paddles 
rotating at 35 rpm.   
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Table 22: Drug Dissolution Rates displayed by three commercial products of Simvastatin 
Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 20-Minutes of their 
dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 0.5% w/v 
of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37oC and 
agitated by paddles rotating at 50 rpm.  
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along 
with their corresponding Standard Deviations which are given in parentheses. 
 
Volume of 
Dissolution 
Medium 
Zocor Tablets 
(G004118) 
mg/min 
Teva 
(25S032) 
mg/min 
Dr. Reddy's 
(C105447) 
mg/min 
500 mL 3.60 (0.00) 3.64 (0.12) 3.76 (0.08) 
900 mL 3.80 (0.02) 3.92 (0.10) 4.00 (0.06) 
 
 
Figure 30:  Drug Dissolution Rates displayed by 3 commercial products of Simvastatin 
Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 20-Minutes of their 
dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 0.5% w/v 
of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37oC and 
agitated by paddles rotating at 50 rpm.  
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Table 23: Drug Dissolution Rates (mg/min) displayed by three commercial products of 
Simvastatin Tablets, USP 80 mg (Zocor-lot#G004118, Teva-lot#25S032 and Dr.Reddy's-
lot#C105447) within the first 20-Minutes of their dissolution in 500 mL or 900 mL (per 
tablet) of an aqueous medium containing 0.5% w/v of SLS in Purified Water maintained 
at 37oC and agitated by paddles rotating at 50 rpm.   
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along 
with their corresponding Standard Deviations (given in parentheses).  
 
Volume of 
Dissolution 
Medium 
Zocor Tablets 
(G004118) 
mg/min 
Teva 
(25S032) 
mg/min 
Dr. Reddy's 
(C105447) 
mg/min 
500 mL 3.32 (0.04) 3.36 (0.08) 2.88 (0.04) 
900 mL 3.40 (0.04) 3.32 (0.13) 4.08 (0.00) 
 
 
Figure 31:  Drug Dissolution Rates (mg/min) displayed by three commercial products of 
Simvastatin Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 20-
Minutes of their dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium 
containing 0.5% w/v of SLS in Purified Water maintained at 37oC and agitated by 
paddles rotating at 50 rpm.    
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Table 24: Drug Dissolution Rates (mg/min) displayed by three commercial products of 
Simvastatin Tablets, USP 80 mg (Zocor-lot#G004118, Teva-lot#25S032 and Dr.Reddy's-
lot#C105447) within the first 20-Minutes of their dissolution in 500 mL or 900 mL (per 
tablet) of an aqueous medium containing 0.5% w/v of SLS in Acetate Buffer pH 4.5 
maintained at 37oC and agitated by paddles rotating at 50 rpm.  
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along 
with their corresponding Standard Deviations (given in parentheses).  
 
Volume of 
Dissolution 
Medium 
Zocor Tablets 
(G004118) 
mg/min 
Teva 
(25S032) 
mg/min 
Dr. Reddy's 
(C105447) 
mg/min 
500 mL 3.16 (0.02) 3.20 (0.06) 3.60 (0.02) 
900 mL 3.20 (0.06) 2.68 (0.04) 3.32 (0.08) 
 
 
Figure 32:  Drug Dissolution Rates (mg/min) displayed by three commercial products of 
Simvastatin Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the 20-Minutes of 
their dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 
0.5% w/v of SLS in Acetate Buffer pH 4.5 maintained at 37oC and agitated by paddles 
rotating at 50 rpm.   
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Table 25: Drug Dissolution Rates displayed by three commercial products of Simvastatin 
Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 30-Minutes of their 
dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 0.5% w/v 
of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37oC and 
agitated by paddles rotating at 35 rpm.  
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along 
with their corresponding Standard Deviations which are given in parentheses. 
 
Volume of 
Dissolution 
Medium 
Zocor Tablets 
(G004118) 
mg/min 
Teva 
(25S032) 
mg/min 
Dr. Reddy's 
(C105447) 
mg/min 
500 mL 2.29 (0.08) 2.29 (0.03) 2.48 (0.13) 
900 mL 2.37 (0.03) 2.29 (0.15) 2.35 (0.03) 
 
 
Figure 33:  Drug Dissolution Rates displayed by 3 commercial products of Simvastatin 
Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 30-Minutes of their 
dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 0.5% w/v 
of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37oC and 
agitated by paddles rotating at 35 rpm.  
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Table 26: Drug Dissolution Rates (mg/min) displayed by three commercial products of 
Simvastatin Tablets, USP 80 mg (Zocor-lot#G004118, Teva-lot#25S032 and Dr.Reddy's-
lot#C105447) within the first 30-Minutes of their dissolution in 500 mL or 900 mL (per 
tablet) of an aqueous medium containing 0.5% w/v of SLS in Purified Water maintained 
at 37oC and agitated by paddles rotating at 35 rpm.   
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along 
with their corresponding Standard Deviations (given in parentheses).  
 
Volume of 
Dissolution 
Medium 
Zocor Tablets 
(G004118) 
mg/min 
Teva 
(25S032) 
mg/min 
Dr. Reddy's 
(C105447) 
mg/min 
500 mL 1.71 (0.06) 1.71 (0.03) 1.89 (0.09) 
900 mL 2.16 (0.04) 2.19 (0.05) 2.37 (0.05) 
 
 
Figure 34:  Drug Dissolution Rates (mg/min) displayed by three commercial products of 
Simvastatin Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 30-
Minutes of their dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium 
containing 0.5% w/v of SLS in Purified Water maintained at 37oC and agitated by 
paddles rotating at 35 rpm.    
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Table 27: Drug Dissolution Rates (mg/min) displayed by three commercial products of 
Simvastatin Tablets, USP 80 mg (Zocor-lot#G004118, Teva-lot#25S032 and Dr.Reddy's-
lot#C105447) within the first 30-Minutes of their dissolution in 500 mL or 900 mL (per 
tablet) of an aqueous medium containing 0.5% w/v of SLS in Acetate Buffer pH 4.5 
maintained at 37oC and agitated by paddles rotating at 35 rpm.  
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along 
with their corresponding Standard Deviations (given in parentheses).  
 
Volume of 
Dissolution 
Medium 
Zocor Tablets 
(G004118) 
mg/min 
Teva 
(25S032) 
mg/min 
Dr. Reddy's 
(C105447) 
mg/min 
500 mL 1.95 (0.02) 2.03 (0.27) 1.65 (0.19) 
900 mL 1.95 (0.07) 1.97 (0.05) 2.03 (0.04) 
 
 
Figure 35:  Drug Dissolution Rates (mg/min) displayed by three commercial products of 
Simvastatin Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the 30-Minutes of 
their dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 
0.5% w/v of SLS in Acetate Buffer pH 4.5 maintained at 37oC and agitated by paddles 
rotating at 35 rpm.   
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Table 28: Drug Dissolution Rates displayed by three commercial products of Simvastatin 
Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 30-Minutes of their 
dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 0.5% w/v 
of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37oC and 
agitated by paddles rotating at 50 rpm.  
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along 
with their corresponding Standard Deviations which are given in parentheses. 
 
Volume of 
Dissolution 
Medium 
Zocor Tablets 
(G004118) 
mg/min 
Teva 
(25S032) 
mg/min 
Dr. Reddy's 
(C105447) 
mg/min 
500 mL 2.28 (0.02) 2.45 (0.07) 2.53 (0.06) 
900 mL 2.56 (0.03) 2.61 (0.07) 2.72 (0.03) 
 
 
Figure 36:  Drug Dissolution Rates displayed by 3 commercial products of Simvastatin 
Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 30-Minutes of their 
dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 0.5% w/v 
of SLS in Phosphate Buffer pH 7.0 (USP dissolution medium) maintained at 37oC and 
agitated by paddles rotating at 50 rpm.  
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Table 29: Drug Dissolution Rates (mg/min) displayed by three commercial products of 
Simvastatin Tablets, USP 80 mg (Zocor-lot#G004118, Teva-lot#25S032 and Dr.Reddy's-
lot#C105447) within the first 30-Minutes of their dissolution in 500 mL or 900 mL (per 
tablet) of an aqueous medium containing 0.5% w/v of SLS in Purified Water maintained 
at 37oC and agitated by paddles rotating at 50 rpm.   
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along 
with their corresponding Standard Deviations (given in parentheses).  
 
Volume of 
Dissolution 
Medium 
Zocor Tablets 
(G004118) 
mg/min 
Teva 
(25S032) 
mg/min 
Dr. Reddy's 
(C105447) 
mg/min 
500 mL 2.13 (0.05) 2.24 (0.02) 1.87 (0.04) 
900 mL 2.26 (0.02) 2.37 (0.07) 2.69 (0.27) 
 
 
Figure 37:  Drug Dissolution Rates (mg/min) displayed by three commercial products of 
Simvastatin Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the first 30-
Minutes of their dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium 
containing 0.5% w/v of SLS in Purified Water maintained at 37oC and agitated by 
paddles rotating at 50 rpm.    
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Table 30: Drug Dissolution Rates (mg/min) displayed by three commercial products of 
Simvastatin Tablets, USP 80 mg (Zocor-lot#G004118, Teva-lot#25S032 and Dr.Reddy's-
lot#C105447) within the first 30-Minutes of their dissolution in 500 mL or 900 mL (per 
tablet) of an aqueous medium containing 0.5% w/v of SLS in Acetate Buffer pH 4.5 
maintained at 37oC and agitated by paddles rotating at 50 rpm.  
The Averages of [mg-of-drug-dissolved-per-minute] from three tablets of each product are reported along 
with their corresponding Standard Deviations (given in parentheses).  
 
Volume of 
Dissolution 
Medium 
Zocor Tablets 
(G004118) 
mg/min 
Teva 
(25S032) 
mg/min 
Dr. Reddy's 
(C105447) 
mg/min 
500 mL 2.26 (0.03) 2.18 (0.02)  2.16 (0.00) 
900 mL 2.08 (0.00) 2.05 (0.03) 2.19 (0.03) 
 
 
Figure 38:  Drug Dissolution Rates (mg/min) displayed by three commercial products of 
Simvastatin Tablets, USP 80 mg (Zocor, Teva and Dr. Reddy's) within the 30-Minutes of 
their dissolution in 500 mL or 900 mL (per tablet) of an aqueous medium containing 
0.5% w/v of SLS in Acetate Buffer pH 4.5 maintained at 37oC and agitated by paddles 
rotating at 50 rpm.   
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 Statistical Analysis 
 The differences between the 10-min, 20-min and 30-min Drug Dissolution Rates 
observed from the Brand Zocor Simvastatin 80 mg Tablets and the Generic Teva or Dr. 
Reddy's Simvastatin products tested in 500 or 900 mL volumes of dissolution media 
under the different dissolution conditions used, were analyzed for statistical significance 
using hypothesis t-testing wherein the t-statistics pertaining to paired comparisons of the 
dissolution rates exhibited by the Zocor vs. Teva and Zocor vs. Dr. Reddy's product-
comparisons, were calculated and compared to two-sided t-distributions with 4 degrees of 
freedom (i.e., 4 d.f.) for statistical significance at P-levels smaller than 5% (i.e., P<0.05) 
and/or 1% (i.e., P<0.01).  Such statistical analysis and comparison results are shown in 
Tables 31-42 and summarized in Tables 43-45. 
Specifically, a hypothesis t-testing for Two-Independent-Groups-with-Unknown-
Variance (Bolton 2004, p. 150) was conducted for each drug dissolution rate observed at 
each dissolution condition by, and between, the brand Zocor product (reference product 
P1) and the generic Teva, or the other generic Dr. Reddy's, products (test products - each 
one P2).  Initially, the Pooled Variance (Sp2) of the compared drug dissolution rate values 
was calculated using their Standard Deviations (i.e., S1 and S2) and sample sizes (i.e., 
N1=3 and N2=3), as follows: 
       (N1 - 1) S12 + (N2 - 1) S22 
   Sp2  =  ------------------------------------- 
                N1 + N2 - 2 
 
After calculating the Pooled Variance (Sp2) and, therefore, estimating the Pooled 
Standard Deviation (Sp which is the square root of Sp2), the corresponding t-statistics (t) 
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were calculated using the means (m1 and m2) of the compared drug dissolution rate 
values displayed by the two products, as follows:   
          | m1 - m2 | 
   t  =  ------------------------------ 
    Sp (1/N1 + 1/N2)1/2 
 
Such t-statistics from each comparison were then evaluated for their statistical 
significance against the corresponding values for statistical significance with 4 degrees of 
freedom (d.f.) at the two-sided t-distribution P-levels of 5% (for P<0.05 when t>t0.95, i.e., 
t>2.78 for 4 d.f.) and/or 1% (for P<0.01 when t>t0.99, i.e., t>4.60 for 4 d.f.), as shown in 
Tables 31-42 and further summarized in Tables 43-45.   
The results, along with the corresponding declarations for statistical significance 
in the differences between the drug dissolution rates displayed by the two compared 
products are tabulated in Tables 31-42.  P-values smaller than 0.05, or even better, P-
values smaller than 0.01, indicate statistically significant differences between the drug 
dissolution rates of each pair of compared products.   
The statistical findings tabulated in Tables 31-42 are compared and further 
explained in the Discussion section below. 
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Table 31:  Statistical Evaluation of Significant Difference (P-values) of the 10-min Drug 
Dissolution Rates displayed in 500 mL of certain Dissolution Media agitated at 35 rpm 
by Branded (Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg.   
The Averages (m1 and m2) from three tablets of each product (N=3) are reported along with their 
corresponding Standard Deviations (S1 and S2) which are given in parentheses. 
 
 
Statistical 
Table 
10-min Drug Dissolution Rate 
(mg/min) 
Evaluation of the Statistical 
Significance of the Difference 
Between the Brand and Generic 
Dissolution 
Medium 
500 mL 
35 rpm 
Zocor 
m1  
(S1) 
Teva 
m2 
(S2) 
Reddy’s 
m2  
(S2) 
t-
statistic 
Statistically 
Significant 
Difference 
P-level  
of 
Significance 
3.12 
(0.71) 
4.80 
(0.20)  3.95 
YES 
t > t0.95 
(t > 2.78) 
Significant 
Difference  
P < 0.05 
Phosphate 
Buffer  
pH 7.0  
with 0.5% 
w/v of SLS 
3.12 
(0.71)  
6.64 
(0.78) 5.78 
YES 
t > t0.99 
(t > 4.60) 
Significant 
Difference  
P < 0.01 
3.52 
(0.76) 
4.72 
(0.08)  2.72 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
Purified 
Water  
with   
0.5% w/v  
of SLS 3.52 (0.76)  
4.64 
(0.44) 2.21 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
2.72 
(1.38) 
5.28 
(0.60)  2.95 
YES 
t > t0.95 
(t > 2.78) 
Significant 
Difference  
P < 0.05 
Acetate 
Buffer  
pH 4.5  
with 0.5% 
w/v of SLS 2.72 (1.38)  
3.68 
(0.42) 1.15 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
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Table 32:  Statistical Evaluation of Significant Difference (P-values) of the 10-min Drug 
Dissolution Rates displayed in 900 mL of certain Dissolution Media agitated at 35 rpm 
by Branded (Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg.   
The Averages (m1 and m2) from three tablets of each product (N=3) are reported along with their 
corresponding Standard Deviations (S1 and S2) which are given in parentheses. 
 
 
Statistical 
Table 
10-min Drug Dissolution Rate 
(mg/min) 
Evaluation of the Statistical 
Significance of the Difference 
Between the Brand and Generic 
Dissolution 
Medium 
900 mL 
35 rpm 
Zocor 
m1  
(S1) 
Teva 
m2 
(S2) 
Reddy’s 
m2  
(S2) 
t-
statistic 
Statistically 
Significant 
Difference 
P-level  
of 
Significance 
3.52 
(1.54) 
3.92 
(1.26)  0.35 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
Phosphate 
Buffer  
pH 7.0  
with 0.5% 
w/v of SLS 
3.52 
(1.54)  
4.00 
(0.72) 0.49 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
3.76 
(0.77) 
5.52 
(0.38)  3.55 
YES 
t > t0.95 
(t > 2.78) 
Significant 
Difference  
P < 0.05 
Purified 
Water  
with   
0.5% w/v  
of SLS 3.76 (0.77)  
5.04 
(0.38) 2.58 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
2.72 
(1.26) 
4.64 
(1.14)  1.96 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
Acetate 
Buffer  
pH 4.5  
with 0.5% 
w/v of SLS 2.72 (1.26)  
4.40 
(0.49) 2.15 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
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Table 33:  Statistical Evaluation of Significant Difference (P-values) of the 10-min Drug 
Dissolution Rates displayed in 500 mL of certain Dissolution Media agitated at 50 rpm 
by Branded (Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg.   
The Averages (m1 and m2) from three tablets of each product (N=3) are reported along with their 
corresponding Standard Deviations (S1 and S2) which are given in parentheses. 
 
 
Statistical 
Table 
10-min Drug Dissolution Rate 
(mg/min) 
Evaluation of the Statistical 
Significance of the Difference 
Between the Brand and Generic 
Dissolution 
Medium 
500 mL 
50 rpm 
Zocor 
m1  
(S1) 
Teva 
m2 
(S2) 
Reddy’s 
m2  
(S2) 
t-
statistic 
Statistically 
Significant 
Difference 
P-level  
of 
Significance 
5.12 
(0.44) 
6.88 
(0.42)  5.01 
YES 
t > t0.99 
(t > 4.60) 
Significant 
Difference  
P < 0.01 
Phosphate 
Buffer  
pH 7.0  
with 0.5% 
w/v of SLS 
5.12 
(0.44)  
6.88 
(0.12) 6.68 
YES 
t > t0.99 
(t > 4.60) 
Significant 
Difference  
P < 0.01 
6.00 
(0.34) 
6.40 
(0.17)  1.82 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
Purified 
Water  
with   
0.5% w/v  
of SLS 6.00 (0.34)  
5.52 
(0.28) 1.89 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
6.24 
(0.26) 
6.56 
(0.21)  1.66 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
Acetate 
Buffer  
pH 4.5  
with 0.5% 
w/v of SLS 6.24 (0.26)  
5.44 
(0.24) 3.92 
YES 
t > t0.95 
(t > 2.78) 
Significant 
Difference  
P < 0.05 
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Table 34:  Statistical Evaluation of Significant Difference (P-values) of the 10-min Drug 
Dissolution Rates displayed in 900 mL of certain Dissolution Media agitated at 50 rpm 
by Branded (Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg.   
The Averages (m1 and m2) from three tablets of each product (N=3) are reported along with their 
corresponding Standard Deviations (S1 and S2) which are given in parentheses. 
 
 
Statistical 
Table 
10-min Drug Dissolution Rate 
(mg/min) 
Evaluation of the Statistical 
Significance of the Difference 
Between the Brand and Generic 
Dissolution 
Medium 
900 mL 
50 rpm 
Zocor 
m1  
(S1) 
Teva 
m2 
(S2) 
Reddy’s 
m2  
(S2) 
t-
statistic 
Statistically 
Significant 
Difference 
P-level  
of 
Significance 
6.08 
(0.73) 
7.12 
(0.20)  2.38 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
Phosphate 
Buffer  
pH 7.0  
with 0.5% 
w/v of SLS 
6.08 
(0.73)  
7.36 
(0.21) 2.92 
YES 
t > t0.95 
(t > 2.78) 
Significant 
Difference  
P < 0.05 
4.40 
(1.26) 
6.24 
(0.29)  2.47 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
Purified 
Water  
with   
0.5% w/v  
of SLS 4.40 (1.26)  
7.76 
(0.12) 4.60 
YES 
t = t0.99 
(t = 4.60) 
Significant 
Difference  
P < 0.01 
5.52 
(0.37) 
6.00 
(0.12)  2.14 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
Acetate 
Buffer  
pH 4.5  
with 0.5% 
w/v of SLS 5.52 (0.37)  
6.08 
(0.10) 2.53 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
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Table 35:  Statistical Evaluation of Significant Difference (P-values) of the 20-min Drug 
Dissolution Rates displayed in 500 mL of certain Dissolution Media agitated at 35 rpm 
by Branded (Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg.   
The Averages (m1 and m2) from three tablets of each product (N=3) are reported along with their 
corresponding Standard Deviations (S1 and S2) which are given in parentheses. 
 
 
Statistical 
Table 
20-min Drug Dissolution Rate 
(mg/min) 
Evaluation of the Statistical 
Significance of the Difference 
Between the Brand and Generic 
Dissolution 
Medium 
500 mL 
35 rpm 
Zocor 
m1  
(S1) 
Teva 
m2 
(S2) 
Reddy’s 
m2  
(S2) 
t-
statistic 
Statistically 
Significant 
Difference 
P-level  
of 
Significance 
3.16 
(0.26) 
3.20 
(0.08)  0.26 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
Phosphate 
Buffer  
pH 7.0  
with 0.5% 
w/v of SLS 
3.16 
(0.26)  
3.60 
(0.25) 2.11 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
2.48 
(0.10) 
2.52 
(0.06)  0.59 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
Purified 
Water  
with   
0.5% w/v  
of SLS 2.48 (0.10)  
2.72 
(0.00) 4.16 
YES 
t > t0.95 
(t > 2.78) 
Significant 
Difference  
P < 0.05 
2.76 
(0.10) 
3.00 
(0.10)  2.94 
YES 
t > t0.95 
(t > 2.78) 
Significant 
Difference  
P < 0.05 
Acetate 
Buffer  
pH 4.5  
with 0.5% 
w/v of SLS 2.76 (0.10)  
2.40 
(0.34) 1.76 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
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Table 36:  Statistical Evaluation of Significant Difference (P-values) of the 20-min Drug 
Dissolution Rates displayed in 900 mL of certain Dissolution Media agitated at 35 rpm 
by Branded (Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg.   
The Averages (m1 and m2) from three tablets of each product (N=3) are reported along with their 
corresponding Standard Deviations (S1 and S2) which are given in parentheses. 
 
 
Statistical 
Table 
20-min Drug Dissolution Rate 
(mg/min) 
Evaluation of the Statistical 
Significance of the Difference 
Between the Brand and Generic 
Dissolution 
Medium 
900 mL 
35 rpm 
Zocor 
m1  
(S1) 
Teva 
m2 
(S2) 
Reddy’s 
m2  
(S2) 
t-
statistic 
Statistically 
Significant 
Difference 
P-level  
of 
Significance 
3.16 
(0.12) 
3.16 
(0.35)  0 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
Phosphate 
Buffer  
pH 7.0  
with 0.5% 
w/v of SLS 
3.16 
(0.12)  
3.16 
(0.17) 0 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
3.04 
(0.10) 
3.32 
(0.08)  3.79 
YES 
t > t0.95 
(t > 2.78) 
Significant 
Difference  
P < 0.05 
Purified 
Water  
with   
0.5% w/v  
of SLS 3.04 (0.10)  
3.40 
(0.16) 3.31 
YES 
t > t0.95 
(t > 2.78) 
Significant 
Difference  
P < 0.05 
2.68 
(0.19) 
2.92 
(0.27)  1.26 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
Acetate 
Buffer  
pH 4.5  
with 0.5% 
w/v of SLS 2.68 (0.19)  
2.84 
(0.10) 1.29 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
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Table 37:  Statistical Evaluation of Significant Difference (P-values) of the 20-min Drug 
Dissolution Rates displayed in 500 mL of certain Dissolution Media agitated at 50 rpm 
by Branded (Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg.   
The Averages (m1 and m2) from three tablets of each product (N=3) are reported along with their 
corresponding Standard Deviations (S1 and S2) which are given in parentheses. 
 
 
Statistical 
Table 
20-min Drug Dissolution Rate 
(mg/min) 
Evaluation of the Statistical 
Significance of the Difference 
Between the Brand and Generic 
Dissolution 
Medium 
500 mL 
50 rpm 
Zocor 
m1  
(S1) 
Teva 
m2 
(S2) 
Reddy’s 
m2  
(S2) 
t-
statistic 
Statistically 
Significant 
Difference 
P-level  
of 
Significance 
3.60 
(0.00) 
3.64 
(0.12)  0.58 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
Phosphate 
Buffer  
pH 7.0  
with 0.5% 
w/v of SLS 
3.60 
(0.00)  
3.76 
(0.08) 3.46 
YES 
t > t0.95 
(t > 2.78) 
Significant 
Difference  
P < 0.05 
3.32 
(0.04) 
3.36 
(0.08)  0.78 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
Purified 
Water  
with   
0.5% w/v  
of SLS 3.32 (0.04)  
2.88 
(0.04) 13.47 
YES 
t > t0.99 
(t > 4.60) 
Significant 
Difference  
P < 0.01 
3.16 
(0.02) 
3.20 
(0.06)  1.10 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
Acetate 
Buffer  
pH 4.5  
with 0.5% 
w/v of SLS 3.16 (0.02)  
3.60 
(0.02) 26.94 
YES 
t > t0.99 
(t > 4.60) 
Significant 
Difference  
P < 0.01 
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Table 38:  Statistical Evaluation of Significant Difference (P-values) of the 20-min Drug 
Dissolution Rates displayed in 900 mL of certain Dissolution Media agitated at 50 rpm 
by Branded (Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg.   
The Averages (m1 and m2) from three tablets of each product (N=3) are reported along with their 
corresponding Standard Deviations (S1 and S2) which are given in parentheses. 
 
 
Statistical 
Table 
20-min Drug Dissolution Rate 
(mg/min) 
Evaluation of the Statistical 
Significance of the Difference 
Between the Brand and Generic 
Dissolution 
Medium 
900 mL 
50 rpm 
Zocor 
m1  
(S1) 
Teva 
m2 
(S2) 
Reddy’s 
m2  
(S2) 
t-
statistic 
Statistically 
Significant 
Difference 
P-level  
of 
Significance 
3.80 
(0.02) 
3.92 
(0.10)  2.04 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
Phosphate 
Buffer  
pH 7.0  
with 0.5% 
w/v of SLS 
3.80 
(0.02)  
4.00 
(0.06) 5.48 
YES 
t > t0.99 
(t > 4.60) 
Significant 
Difference  
P < 0.01 
3.40 
(0.04) 
3.32 
(0.13)  1.02 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
Purified 
Water  
with   
0.5% w/v  
of SLS 3.40 (0.04)  
4.08 
(0.00) 29.45 
YES 
t > t0.99 
(t > 4.60) 
Significant 
Difference  
P < 0.01 
3.20 
(0.06) 
2.68 
(0.04)  12.49 
YES 
t > t0.99 
(t > 4.60) 
Significant 
Difference  
P < 0.01 
Acetate 
Buffer  
pH 4.5  
with 0.5% 
w/v of SLS 3.20 (0.06)  
3.32 
(0.08) 2.08 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
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Table 39:  Statistical Evaluation of Significant Difference (P-values) of the 30-min Drug 
Dissolution Rates displayed in 500 mL of certain Dissolution Media agitated at 35 rpm 
by Branded (Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg.   
The Averages (m1 and m2) from three tablets of each product (N=3) are reported along with their 
corresponding Standard Deviations (S1 and S2) which are given in parentheses. 
 
 
Statistical 
Table 
30-min Drug Dissolution Rate 
(mg/min) 
Evaluation of the Statistical 
Significance of the Difference 
Between the Brand and Generic 
Dissolution 
Medium 
500 mL 
35 rpm 
Zocor 
m1  
(S1) 
Teva 
m2 
(S2) 
Reddy’s 
m2  
(S2) 
t-
statistic 
Statistically 
Significant 
Difference 
P-level  
of 
Significance 
2.29 
(0.08) 
2.29 
(0.08)  0 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
Phosphate 
Buffer  
pH 7.0  
with 0.5% 
w/v of SLS 
2.29 
(0.08)  
2.48 
(0.13) 2.16 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
1.71 
(0.06) 
1.71 
(0.03)  0 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
Purified 
Water  
with   
0.5% w/v  
of SLS 1.71 (0.06)  
1.89 
(0.09) 2.88 
YES 
t > t0.95 
(t > 2.78) 
Significant 
Difference  
P < 0.05 
1.95 
(0.02) 
2.03 
(0.27)  0.51 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
Acetate 
Buffer  
pH 4.5  
with 0.5% 
w/v of SLS 1.95 (0.02)  
1.65 
(0.19) 2.72 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
 
	   76	  
 
Table 40:  Statistical Evaluation of Significant Difference (P-values) of the 30-min Drug 
Dissolution Rates displayed in 900 mL of certain Dissolution Media agitated at 35 rpm 
by Branded (Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg.   
The Averages (m1 and m2) from three tablets of each product (N=3) are reported along with their 
corresponding Standard Deviations (S1 and S2) which are given in parentheses. 
 
 
Statistical 
Table 
30-min Drug Dissolution Rate 
(mg/min) 
Evaluation of the Statistical 
Significance of the Difference 
Between the Brand and Generic 
Dissolution 
Medium 
900 mL 
35 rpm 
Zocor 
m1  
(S1) 
Teva 
m2 
(S2) 
Reddy’s 
m2  
(S2) 
t-
statistic 
Statistically 
Significant 
Difference 
P-level  
of 
Significance 
2.37 
(0.03) 
2.29 
(0.15)  0.91 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
Phosphate 
Buffer  
pH 7.0  
with 0.5% 
w/v of SLS 
2.37 
(0.03)  
2.35 
(0.03) 0.82 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
2.16 
(0.04) 
2.19 
(0.05)  0.81 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
Purified 
Water  
with   
0.5% w/v  
of SLS 2.16 (0.04)  
2.37 
(0.05) 5.68 
YES 
t > t0.99 
(t > 4.60) 
Significant 
Difference  
P < 0.01 
1.95 
(0.07) 
1.97 
(0.05)  0.4 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
Acetate 
Buffer  
pH 4.5  
with 0.5% 
w/v of SLS 1.95 (0.07)  
2.03 
(0.04) 1.72 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
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Table 41:  Statistical Evaluation of Significant Difference (P-values) of the 30-min Drug 
Dissolution Rates displayed in 500 mL of certain Dissolution Media agitated at 50 rpm 
by Branded (Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg.   
The Averages (m1 and m2) from three tablets of each product (N=3) are reported along with their 
corresponding Standard Deviations (S1 and S2) which are given in parentheses. 
 
 
Statistical 
Table 
30-min Drug Dissolution Rate 
(mg/min) 
Evaluation of the Statistical 
Significance of the Difference 
Between the Brand and Generic 
Dissolution 
Medium 
500 mL 
50 rpm 
Zocor 
m1  
(S1) 
Teva 
m2 
(S2) 
Reddy’s 
m2  
(S2) 
t-
statistic 
Statistically 
Significant 
Difference 
P-level  
of 
Significance 
2.28 
(0.02) 
2.45 
(0.07)  4.05 
YES 
t > t0.95 
(t > 2.78) 
Significant 
Difference  
P < 0.05 
Phosphate 
Buffer  
pH 7.0  
with 0.5% 
w/v of SLS 
2.28 
(0.02)  
2.53 
(0.06) 6.85 
YES 
t > t0.99 
(t > 4.60) 
Significant 
Difference  
P < 0.01 
2.13 
(0.05) 
2.24 
(0.02)  3.54 
YES 
t > t0.95 
(t > 2.78) 
Significant 
Difference  
P < 0.05 
Purified 
Water  
with   
0.5% w/v  
of SLS 2.13 (0.05)  
1.87 
(0.04) 7.03 
YES 
t > t0.99 
(t > 4.60) 
Significant 
Difference  
P < 0.01 
2.26 
(0.03) 
2.18 
(0.02)  3.84 
YES 
t > t0.95 
(t > 2.78) 
Significant 
Difference  
P < 0.05 
Acetate 
Buffer  
pH 4.5  
with 0.5% 
w/v of SLS 2.26 (0.03)  
2.26 
(0.00) 0 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
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Table 42:  Statistical Evaluation of Significant Difference (P-values) of the 30-min Drug 
Dissolution Rates displayed in 900 mL of certain Dissolution Media agitated at 50 rpm 
by Branded (Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg.   
The Averages (m1 and m2) from three tablets of each product (N=3) are reported along with their 
corresponding Standard Deviations (S1 and S2) which are given in parentheses. 
 
 
Statistical 
Table 
30-min Drug Dissolution Rate 
(mg/min) 
Evaluation of the Statistical 
Significance of the Difference 
Between the Brand and Generic 
Dissolution 
Medium 
900 mL 
50 rpm 
Zocor 
m1  
(S1) 
Teva 
m2 
(S2) 
Reddy’s 
m2  
(S2) 
t-
statistic 
Statistically 
Significant 
Difference 
P-level  
of 
Significance 
2.56 
(0.03) 
2.61 
(0.07)  1.14 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
Phosphate 
Buffer  
pH 7.0  
with 0.5% 
w/v of SLS 
2.56 
(0.03)  
2.72 
(0.03) 6.53 
YES 
t > t0.99 
(t > 4.60) 
Significant 
Difference  
P < 0.01 
2.26 
(0.02) 
2.37 
(0.07)  2.62 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
Purified 
Water  
with   
0.5% w/v  
of SLS 2.26 (0.02)  
2.69 
(0.27) 2.75 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
2.08 
(0.00) 
2.05 
(0.03)  1.73 
NO 
t < t0.95 
(t < 2.78) 
Insignificant 
Difference at 
the 5% level 
Acetate 
Buffer  
pH 4.5  
with 0.5% 
w/v of SLS 2.08 (0.00)  
2.19 
(0.03) 6.35 
YES 
t > t0.99 
(t > 4.60) 
Significant 
Difference  
P < 0.01 
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Further Statistical Tabulations 
In order to evaluate more easily and compare the findings of the various statistical 
hypothesis t-testing conducted in this study, all statistical comparisons of the dissolution 
rates observed at the different dissolution conditions used, namely, dissolution volumes 
of 500 mL and 900 mL and agitation speeds of 35 rpm and 50 rpm, for each dissolution 
medium used, namely, aqueous solutions of 0.5% w/v SLS in Phosphate Buffer pH 7.0, 
Purified Water, and Acetate Buffer pH 4.5, respectively, are summarized and compared 
again in Tables 43-45, respectively, wherein P-levels smaller than 5% (i.e., P<0.05) are 
considered sufficient to declare a statistically significant difference between the 10-min, 
20-min or 30-min drug dissolution rates of each pair of products tested.  In addition, 
whenever the calculated t-statistic values (previously tabulated in Tables 31-42) were 
sufficient to declare statistically significant differences between the drug dissolution rates 
of the tested product-pairs at a P-level smaller than 1% (i.e., P<0.01), such level of 
statistical significance is also reported in Tables 43-45 below. 
It should be noted that differences between dissolution rates at P<0.01 are 
statistically more significant than those declared at P<0.05.  In essence, when a difference 
between the dissolution rates of two products is declared as being statistically significant 
at P<0.05, this means that there is not more than 5% probability for such declaration of 
statistical significance to be actually wrong.  Therefore, a declaration of significance at 
P<0.01 whereas, now, there is not more than 1% chance for such declaration to be wrong, 
increases the certainty of the conclusion that the compared dissolution rates are different. 
The statistical findings summarized in Tables 43-45 are further compared and 
more elaborated in the Discussion section below. 
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Table 43:  Statistical Comparison of the Drug Dissolution Rates displayed by Branded 
(Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg, in two 
different dissolution volumes (per vessel) of an aqueous medium consisting of 0.5% w/v 
SLS in Phosphate Buffer pH 7.0 agitated by paddles rotating at two different speeds.   
A P-value smaller than 0.05 indicates statistically significant difference between the drug dissolution rates 
of the compared products, whereas P-values greater than 0.05 indicate statistical similarity of the rates. 
 
Dissolution Conditions 
(Phosphate Buffer pH 7.0 with 0.5% w/v SLS) 
Statistically Significant Difference 
Between the Brand and Generic 
Drug 
Dissolution 
Rate 
Dissolution 
Volume (mL) 
Agitation 
Speed (rpm) 
Zocor (Brand)  
vs. 
Teva (Generic) 
Zocor (Brand)  
vs. 
Reddy’s (Generic) 
35 rpm YES P < 0.05 
YES 
P < 0.01 
500 mL 
50 rpm YES P < 0.05 
YES 
P < 0.05 
35 rpm NO P > 0.05 
NO 
P > 0.05 
10-min 
Drug 
Dissolution 
Rate 
900 mL 
50 rpm NO P > 0.05 
YES 
P < 0.05 
35 rpm NO P > 0.05 
NO 
P > 0.05 
500 mL 
50 rpm NO P > 0.05 
YES 
P < 0.05 
35 rpm NO P > 0.05 
NO 
P > 0.05 
20-min 
Drug 
Dissolution 
Rate 
900 mL 
50 rpm NO P > 0.05 
YES 
P < 0.01 
35 rpm NO P > 0.05 
NO 
P > 0.05 
500 mL 
50 rpm YES P < 0.05 
YES 
P < 0.01 
35 rpm NO P > 0.05 
NO 
P > 0.05 
30-min 
Drug 
Dissolution 
Rate 
900 mL 
50 rpm NO P > 0.05 
YES 
P < 0.01 
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Table 44:  Statistical Comparison of the Drug Dissolution Rates displayed by Branded 
(Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg, in two 
different dissolution volumes (per vessel) of an aqueous medium consisting of 0.5% w/v 
SLS in Purified Water agitated by paddles rotating at two different speeds.   
A P-value smaller than 0.05 indicates statistically significant difference between the drug dissolution rates 
of the compared products, whereas P-values greater than 0.05 indicate statistical similarity of the rates. 
 
Dissolution Conditions 
(Purified Water with 0.5% w/v SLS) 
Statistically Significant Difference 
Between the Brand and Generic 
Drug 
Dissolution 
Rate 
Dissolution 
Volume (mL) 
Agitation 
Speed (rpm) 
Zocor (Brand)  
vs. 
Teva (Generic) 
Zocor (Brand)  
vs. 
Reddy’s (Generic) 
35 rpm NO P > 0.05 
NO 
P > 0.05 
500 mL 
50 rpm NO P > 0.05 
NO 
P > 0.05 
35 rpm YES P < 0.05 
NO 
P > 0.05 
10-min 
Drug 
Dissolution 
Rate 
900 mL 
50 rpm NO P > 0.05 
YES 
P < 0.05 
35 rpm NO P > 0.05 
YES 
P < 0.05 
500 mL 
50 rpm NO P > 0.05 
YES 
P < 0.01 
35 rpm YES P < 0.05 
YES 
P < 0.05 
20-min 
Drug 
Dissolution 
Rate 
900 mL 
50 rpm NO P > 0.05 
YES 
P < 0.01 
35 rpm NO P > 0.05 
YES 
P < 0.05 
500 mL 
50 rpm YES P < 0.05 
YES 
P < 0.01 
35 rpm NO P > 0.05 
YES 
P < 0.01 
30-min 
Drug 
Dissolution 
Rate 
900 mL 
50 rpm NO P > 0.05 
NO 
P > 0.05 
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Table 45:  Statistical Comparison of the Drug Dissolution Rates displayed by Branded 
(Zocor) and Generic (Teva or Dr. Reddy’s) Simvastatin Tablets, USP 80 mg, in two 
different dissolution volumes (per vessel) of an aqueous medium consisting of 0.5% w/v 
SLS in Acetate Buffer pH 4.5 agitated by paddles rotating at two different speeds.   
A P-value smaller than 0.05 indicates statistically significant difference between the drug dissolution rates 
of the compared products, whereas P-values greater than 0.05 indicate statistical similarity of the rates. 
 
Dissolution Conditions 
(Acetate Buffer pH 4.5 with 0.5% w/v SLS) 
Statistically Significant Difference 
Between the Brand and Generic 
Drug 
Dissolution 
Rate 
Dissolution 
Volume (mL) 
Agitation 
Speed (rpm) 
Zocor (Brand)  
vs. 
Teva (Generic) 
Zocor (Brand)  
vs. 
Reddy’s (Generic) 
35 rpm YES P < 0.05 
NO 
P > 0.05 
500 mL 
50 rpm NO P > 0.05 
YES 
P < 0.05 
35 rpm NO P > 0.05 
NO 
P > 0.05 
10-min 
Drug 
Dissolution 
Rate 
900 mL 
50 rpm NO P > 0.05 
NO 
P > 0.05 
35 rpm YES P < 0.05 
NO 
P > 0.05 
500 mL 
50 rpm NO P > 0.05 
YES 
P < 0.01 
35 rpm NO P > 0.05 
NO 
P > 0.05 
20-min 
Drug 
Dissolution 
Rate 
900 mL 
50 rpm YES P < 0.01 
NO 
P > 0.05 
35 rpm NO P > 0.05 
NO 
P > 0.05 
500 mL 
50 rpm YES P < 0.05 
NO 
P > 0.05 
35 rpm NO P > 0.05 
NO 
P > 0.05 
30-min 
Drug 
Dissolution 
Rate 
900 mL 
50 rpm NO P > 0.05 
YES 
P < 0.01 
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DISCUSSION 
 
Comparison of the 10-min Drug Dissolution Rates  
The 10-min drug dissolution rates observed from the three marketed products of 
Simvastatin 80 mg tablets manufactured by Merck (Brand Zocor), Teva (First Generic) 
and Dr. Reddy's (Second Generic) dissolving in 500 mL and 900 mL volumes of three 
aqueous solutions of 0.5% w/v of Sodium Lauryl Sulfate (SLS) contained in Phosphate 
Buffer pH 7.0, Purified Water and Acetate Buffer pH 4.5, maintained at 37oC and 
agitated by paddles rotating at 35 and 50 rpm, are compared in Tables 13-18 and plotted 
as bar-graphs in Figures 21-26. 
It is apparent that the majority of the 10-min drug dissolution rates exhibited by 
all three Simvastatin products possess relatively high variability expressed in the form of 
increased standard deviations, in all three dissolution media and in both agitation speeds 
and dissolution volumes used in this study's dissolution tests.  Consequently, visual 
observations of the drug dissolution rate differences between the three compared products 
of Simvastatin 80 mg tablets cannot ensure correct and realistic correlations between the 
in-vitro and in-vivo performances of the three products.  Instead, in order to ensure fair 
comparisons, statistical analysis was performed using hypothesis t-testing which takes 
into consideration the standard deviations of the compared drug dissolution rates.   
Such statistical t-testing results of the 10-min drug dissolution rates exhibited by 
the Brand Zocor and the Generic Teva or Dr. Reddy's products are tabulated in Tables 
31-34 and further summarized in Tables 43-45.  As shown there, statistically significant 
differences between the 10-min drug dissolution rates of the Zocor vs. Teva and Zocor 
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vs. Reddy's product-comparisons were observed at both 35 and 50 rpm when 500 mL of 
Phosphate Buffer pH 7.0 with 0.5% w/v SLS was used as the dissolution medium, and 
only for the Zocor vs. Reddy's product-comparison at 900 mL of the same medium 
agitated using paddles rotating at 50 rpm.  On the other hand, when 900 mL of Purified 
Water with 0.5% w/v SLS was used as the dissolution medium, the 10-min dissolution 
rates of the Zocor vs. Teva product-comparison presented a statistically significant 
difference at 35 rpm, and those of the Zocor vs. Reddy's product-comparison at 50 rpm.  
Finally, statistically significant differences between the 10-min drug dissolution rates of 
the Zocor vs. Teva product-comparison were observed only at 35 rpm, and of the Zocor 
vs. Reddy's product-comparison at 50 rpm, when 500 mL of Acetate Buffer pH 4.5 with 
0.5% w/v SLS was used as the dissolution medium. 
It should be emphasized at this point that the three Simvastatin products compared 
in this study are known to be bioequivalent to each other since they have been clinically 
tested and proved to be bioequivalent to each other in controlled and FDA-approved 
bioequivalence studies.  Therefore, dissolution testing conditions yielding 10-min drug 
dissolution rates of the Zocor vs. Teva and Zocor vs. Reddy's product-comparisons that 
do not exhibit statistically significant differences should be considered as dissolution 
procedures that demonstrate dependable in-vitro/in-vivo correlations and are capable to 
predict the in-vivo drug absorption characteristics of the products including the 
bioequivalence of both of the Generic Simvastatin products (i.e., Teva and Dr. Reddy's) 
to the Brand Zocor product. 
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Therefore, based on this study, it seems that the 10-min Drug Dissolution Rate 
can be used as a reliable predictive tool of bioequivalence between a generic Simvastatin 
product and the brand Zocor, when the following dissolution testing conditions are used: 
(i) 900 mL of Phosphate Buffer pH 7.0 with 0.5% w/v SLS, agitated at 35 rpm; 
(ii) 500 mL of Purified Water with 0.5% w/v SLS, agitated at 35 rpm; 
(iii) 500 mL of Purified Water with 0.5% w/v SLS, agitated at 50 rpm; 
(iv) 900 mL of Acetate Buffer pH 4.5 with 0.5% w/v SLS, agitated at 35 rpm; and 
(v) 900 mL of Acetate Buffer pH 4.5 with 0.5% w/v SLS, agitated at 50 rpm. 
 
 
Comparison of the 20-min Drug Dissolution Rates  
The 20-min drug dissolution rates observed from the three marketed products of 
Simvastatin 80 mg tablets dissolving in 500 mL and 900 mL volumes of three aqueous 
solutions of 0.5% w/v of SLS contained in Phosphate Buffer pH 7.0, Purified Water and 
Acetate Buffer pH 4.5, maintained at 37oC and agitated by paddles rotating at 35 and 50 
rpm, are compared in Tables 19-24 and plotted as bar-graphs in Figures 27-32. 
In contrast to the 10-min dissolution rates, the majority of the 20-min drug 
dissolution rates exhibited by all three Simvastatin products possess relatively low 
variability expressed in the form of smaller standard deviations, in all three dissolution 
media, at both agitation speeds and in both dissolution volumes used in this study's 
dissolution testing procedures.  Consequently, visual observations of the drug dissolution 
rate differences between the three compared products of Simvastatin 80 mg tablets are 
more reliable in drawing correct and realistic correlations between the in-vitro and in-vivo 
performances of the products.  However, in order to ensure fair comparisons, statistical 
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analysis was also performed using hypothesis t-testing which takes into consideration the 
averages and standard deviations of the compared 20-min drug dissolution rates.   
Such statistical t-testing results of the 20-min drug dissolution rates exhibited by 
the Brand Zocor and the Generic Teva or Dr. Reddy's product-comparisons are tabulated 
in Tables 35-38 and further summarized in Tables 43-45.  As shown there, statistically 
significant differences between the 20-min drug dissolution rates of only the Zocor vs. 
Reddy's product-comparison were observed when both 500 and 900 mL of Phosphate 
Buffer pH 7.0 with 0.5% w/v SLS was used as the dissolution medium, agitated using 
paddles rotating only at 50 rpm (and not at 35 rpm).  On the other hand, when 500 and 
900 mL of Purified Water with 0.5% w/v SLS was used as the dissolution medium, the 
20-min dissolution rates of the Zocor vs. Reddy's product-comparison presented a 
statistical significant difference at both 35 and 50 rpm, and those of the Zocor vs. Teva 
product-comparison at 900 mL of the same medium agitated only at 35 rpm.  Finally, 
statistically significant differences between the 20-min drug dissolution rates of the Zocor 
vs. Teva product-comparison were observed when 500 mL of Acetate Buffer pH 4.5 with 
0.5% w/v SLS was used as the dissolution medium agitated at 35 rpm and, similarly, 
when 900 mL of the same medium was agitated at 50 rpm.  In addition, statistically 
significant differences between the 20-min drug dissolution rates of the Zocor vs. Reddy's 
product-comparison were also observed when 500 mL of Acetate Buffer pH 4.5 with 
0.5% w/v SLS was agitated at 50 rpm. 
As discussed previously, the three Simvastatin products compared in this study 
are known to be bioequivalent to each other since they have been clinically tested and 
proved to be bioequivalent to each other in controlled and FDA-approved bioequivalence 
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studies.  Therefore, dissolution testing conditions yielding 20-min drug dissolution rates 
of the Zocor vs. Teva and Zocor vs. Reddy's product-comparisons that do not exhibit 
statistically significant differences should be considered as dissolution procedures that 
demonstrate dependable in-vitro/in-vivo correlations and are capable to predict the in-vivo 
drug absorption characteristics of the products, including the bioequivalence of both of 
the Generic products (i.e., Teva and Dr. Reddy's) to the Brand Zocor product. 
Therefore, based on this study, it seems that the 20-min Drug Dissolution Rate 
can be used as a reliable predictive tool of bioequivalence between a generic Simvastatin 
product and the brand Zocor, when the following dissolution testing conditions are used: 
(i) 500 mL of Phosphate Buffer pH 7.0 with 0.5% w/v SLS, agitated at 35 rpm; 
(ii) 900 mL of Phosphate Buffer pH 7.0 with 0.5% w/v SLS, agitated at 35 rpm; and 
(iii) 900 mL of Acetate Buffer pH 4.5 with 0.5% w/v SLS, agitated at 35 rpm. 
 
 
Comparison of the 30-min Drug Dissolution Rates  
The 30-min drug dissolution rates observed from the three marketed products of 
Simvastatin 80 mg tablets dissolving in 500 mL and 900 mL volumes of three aqueous 
solutions of 0.5% w/v of SLS contained in Phosphate Buffer pH 7.0, Purified Water and 
Acetate Buffer pH 4.5, maintained at 37oC and agitated by paddles rotating at 35 and 50 
rpm, are compared in Tables 25-30 and plotted as bar-graphs in Figures 33-38. 
Here again and in contrast to the 10-min dissolution rates, the 30-min drug 
dissolution rates exhibited by all three Simvastatin products possess low variability 
expressed in the form of very small standard deviations, in all three dissolution media, at 
both agitation speeds and in both dissolution volumes used in this study's dissolution 
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testing procedures.  Consequently, visual observations of the drug dissolution rate 
differences between the three compared products of Simvastatin 80 mg tablets are quite 
reliable in drawing correct and realistic correlations between the in-vitro and in-vivo 
performances of the three products.  Ultimately, however, and in order to ensure fair 
comparisons, statistical analysis was also performed using hypothesis t-testing which 
takes into consideration the averages and standard deviations of the compared 30-min 
drug dissolution rates.   
Such statistical t-testing results of the 30-min drug dissolution rates exhibited by 
the Brand Zocor and the Generic Teva or Dr. Reddy's products are tabulated in Tables 
39-42 and further summarized in Tables 43-45.  As shown there, statistically significant 
differences between the 30-min drug dissolution rates of the Zocor vs. Teva and Zocor 
vs. Reddy's product-comparisons were observed when 500 mL of Phosphate Buffer pH 
7.0 with 0.5% w/v SLS was used as the dissolution medium, agitated using paddles 
rotating at 50 rpm.  In addition, statistically significant differences between the 30-min 
drug dissolution rates of the Zocor vs. Reddy's product-comparison were also observed 
when 900 mL of Phosphate Buffer pH 7.0 with 0.5% w/v SLS was agitated at 50 rpm.  
On the other hand, when 500 mL of Purified Water with 0.5% w/v SLS was used as the 
dissolution medium, the 30-min dissolution rates of both the Zocor vs. Teva and Zocor 
vs. Reddy's product-comparisons presented a statistical significant difference at 50 rpm, 
and those of the Zocor vs. Reddy's product-comparison at 500 and 900 mL of the same 
medium agitated at 35 rpm.  Finally, statistically significant differences between the 30-
min dissolution rates of the Zocor vs. Teva product-comparison were observed when 500 
mL of Acetate Buffer pH 4.5 with 0.5% w/v SLS was used as the dissolution medium 
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agitated at 50 rpm, and between the 30-min drug dissolution rates of the Zocor vs. 
Reddy's product-comparison when 900 mL of the same dissolution medium was agitated 
at 50 rpm. 
As discussed previously, the three Simvastatin products compared in this study 
are known to be bioequivalent to each other since they have been clinically tested and 
proved to be bioequivalent to each other in controlled and FDA-approved bioequivalence 
studies.  Therefore, dissolution testing conditions yielding 30-min drug dissolution rates 
of the Zocor vs. Teva and Zocor vs. Reddy's product-comparisons that do not exhibit 
statistically significant differences should be considered as dissolution procedures that 
demonstrate dependable in-vitro/in-vivo correlations and are capable to predict the in-vivo 
drug absorption characteristics of the products, including the bioequivalence of both of 
the Generic products (i.e., Teva and Dr. Reddy's) to the Brand Zocor product. 
Therefore, based on this study, it seems that the 30-min Drug Dissolution Rate 
can be used as a reliable predictive tool of bioequivalence between a generic Simvastatin 
product and the brand Zocor, when the following dissolution testing conditions are used: 
(i) 500 mL of Phosphate Buffer pH 7.0 with 0.5% w/v SLS, agitated at 35 rpm; 
(ii) 900 mL of Phosphate Buffer pH 7.0 with 0.5% w/v SLS, agitated at 35 rpm; 
(iii) 900 mL of Purified Water with 0.5% w/v SLS, agitated at 50 rpm; 
(iv) 500 mL of Acetate Buffer pH 4.5 with 0.5% w/v SLS, agitated at 35 rpm; and 
(v) 900 mL of Acetate Buffer pH 4.5 with 0.5% w/v SLS, agitated at 35 rpm. 
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CONCLUSION 
 
This study reveals that similarities of the 10-min, 20-min and 30-min drug 
dissolution rates exhibited by the three bioequivalent products investigated in this study, 
are basically dependent upon the type of dissolution media and conditions used to test 
these three Simvastatin products.  Specifically, it appears that the drug solubility in the 
dissolution medium used, as expressed by the volume, acidity and buffer capacity of the 
medium, play an important role in creating a testing environment which may yield similar 
drug dissolution rates of the tested products, as expected to be the case since all three 
products have been already proven in controlled and FDA-approved clinical studies to be 
bioequivalent to each other.   
In essence, one should investigate whether any of the three dissolution media used 
in this study, under any dissolution conditions employed in this study, were able to 
simultaneously produce 10-min, 20-min and 30-min drug dissolution rates of the branded 
Zocor product that were statistically similar to those of both the generic Teva and Dr. 
Reddy's Simvastatin products.  If such dissolution medium and testing conditions exist, 
then this study can be considered as one that resulted in the establishment of a dissolution 
test which may present dependable in-vitro/in-vivo correlations and reliable predictive 
power of bioequivalence. 
Based on the work conducted and results obtained in this study, it seems that two 
such dissolution tests have been discovered in this research project as shown in Tables 43 
and 45 and further described in the foregoing Discussion section.  The following two 
dissolution tests predict bioequivalence: 
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(1)  900 mL (per vessel) of an aqueous medium containing 0.5% w/v SLS in 
 Phosphate Buffer pH 7.0 (i.e., the USP dissolution medium), maintained 
 at 37oC and agitated at 35 rpm (via paddles); and/or 
   
(2)  900 mL (per vessel) of an aqueous medium containing 0.5% w/v SLS in 
 Acetate Buffer pH 4.5, maintained at 37oC and agitated at 35 rpm (via 
 paddles). 
   
In conclusion, if a laboratory attempts to develop a new generic product of 
Simvastatin 80 mg Tablets that are bioequivalent to the branded Zocor Simvastatin 80 mg 
Tablets, then the new product must be formulated in such a way that, when tested for its 
dissolution profile using 900 mL (per vessel in which one tablet is dissolved/tested) of an 
aqueous medium containing either 0.5% w/v SLS in Phosphate Buffer pH 7.0 and/or 
0.5% w/v SLS in Acetate Buffer pH 4.5, maintained at 37oC and agitated using paddles 
rotating at 35 rpm, its 10-min, 20-min and 30-min drug dissolution rates should be 
statistically similar to those obtained from the same testing of the branded Zocor 80 mg 
Tablets. 
If the above conclusions are correct and these two dissolution testing procedures 
can appropriately predict bioequivalence between a new, experimental generic 
Simvastatin product and its commercial branded Zocor counterpart, then the dissolution 
tests discovered and proposed in this work may be used as invaluable formulation tools in 
order to develop new generic products in a timely and cost-efficient manner of 
Simvastatin 80 mg Tablets.  
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